System and method for prediction of protein-ligand bioactivity using point-cloud machine learning

ABSTRACT

A system and method that predicts whether a given protein-ligand pair is active or inactive, the ground-truth protein-ligand complex crystalline-structure similarity, and an associated bioactivity value. The system and method further produce 3-D visualizations of previously unknown protein-ligand pairs that show directly the importance assigned to protein-ligand interactions, the positive/negative-ness of the saliencies, and magnitude. Furthermore, the system and method make enhancements in the art by accurately predicting protein-ligand pair bioactivity from decoupled models, removing the need for docking simulations, as well as restricting attention of the machine learning between protein and ligand atoms only.

CROSS-REFERENCE TO RELATED APPLICATIONS

Priority is claimed in the application data sheet to the followingpatents or patent applications, the entire written description of eachof which is expressly incorporated herein by reference in its entirety:

Ser. No. 17/202,722

Ser. No. 17/174,677

Ser. No. 17/171,494

Ser. No. 17/166,435

63/126,349

63/126,372

63/126,388

BACKGROUND Field of the Art

The disclosure relates to the field of medical research, and moreparticularly to the field of prediction of the bioactivity interactionsbetween molecules and proteins using point-cloud representation andanalysis.

Discussion of the State of the Art

Pharmaceutical research is hindered by the complexity of protein-ligandinteractions. Proteins are macromolecules involved in a large array ofbiological functions, comprising long chains of amino acids, each ofwhich is itself an organic molecule. The shape of proteins determinestheir bioactivity, and the shape of a protein is determined by the waythe protein folds based on its molecular structure. The complexity ofproteins and their folding patterns makes their final shapescomputationally intractable.

Ligands further complicate the issue as each ligand further changes theshape of the protein, which changes its bioactivity. Inferring theinteraction between a protein and a ligand alone is a computationallydifficult task because proteins are two or three orders of magnitudelarger than a typical ligand and the number of possible interactionsites is very large. Further, each ligand further changes the shape ofthe protein, which changes its bioactivity, and the possible spatialconformations of a protein is several orders of magnitude larger than aligand.

What is needed is a system and method for computationally tractableprediction of protein-ligand interactions and their bioactivity using apoint-cloud machine learning model.

SUMMARY

Accordingly, the inventor has conceived and reduced to practice, asystem and method that predicts whether a given protein-ligand pair isactive or inactive, the ground-truth protein-ligand complexcrystalline-structure similarity, and an associated bioactivity value.The system and method further produce 3-D visualizations of previouslyunknown protein-ligand pairs that show directly the importance assignedto protein-ligand interactions, the positive/negative-ness of thesaliencies, and magnitude. Furthermore, the system and method makeenhancements in the art by accurately predicting protein-ligand pairbioactivity from decoupled models, removing the need for dockingsimulations, as well as restricting attention of the machine learningbetween protein and ligand atoms only. The ground-truth protein-ligandcomplex crystalline-structure similarity refers to crystal structures ofa ligand bound to a protein.

According to a first preferred embodiment, a system for prediction ofprotein-ligand bioactivity comprising: a computing device comprising amemory and a processor; a point-cloud based bioactivity modulecomprising a first plurality of programming instructions stored in thememory and operating on the processor, wherein the first plurality ofprogramming instructions causes the computing device to: receive amolecular structure file, wherein the molecular structure file comprisesmolecular and structural information about at least one protein and oneligand; generate a graph-based neural network of the protein, whereinedges of the graph-based neural network of the protein are determinedusing the molecular structure file; generate a graph-based neuralnetwork of the ligand, wherein edges of the graph-based neural networkof the ligand are determined using the molecular structure file;concatenate a set of vectors from both the graph-based neural network ofthe protein and the graph-based neural network of the ligand; performrestricted-cross-attention learning on the concatenated vectors;generate a single feature vector from the restricted-cross-attentionlearning; use the single feature vector in a feed-forward neural networkto produce one or more outputs selected from the group consisting ofactive or inactive classification, crystalline-structure similarity, andregression analysis; and use the one or more outputs to produce one ormore bioactivity predictions about one or more protein-ligand pairs.

According to a second preferred embodiment, a method for prediction ofprotein-ligand bioactivity comprising the steps of: receiving amolecular structure file, wherein the molecular structure file comprisesmolecular and structural information about at least one protein and oneligand; generating a graph-based neural network of the protein, whereinedges of the graph-based neural network of the protein are determinedusing the molecular structure file; generating a graph-based neuralnetwork of the ligand, wherein edges of the graph-based neural networkof the ligand are determined using the molecular structure file;concatenating a set of vectors from both the graph-based neural networkof the protein and the graph-based neural network of the ligand;performing restricted-cross-attention learning on the concatenatedvectors; generating a single feature vector from therestricted-cross-attention learning; using the single feature vector ina feed-forward neural network to produce one or more outputs selectedfrom the group consisting of active or inactive classification,crystalline-structure similarity, and regression analysis; and using theone or more outputs to produce one or more bioactivity predictions aboutone or more protein-ligand pairs.

According to various aspects of the invention; wherein dockingsimulations are performed on the protein and the ligand from themolecular structure file if the protein and the ligand are coupled;wherein the vector from the graph-based neural network of the proteincomprises atoms within 4 angstroms of the ligand if the protein and theligand are coupled; wherein the vector from the graph-based neuralnetwork of the protein comprises atoms of a binding pocket if theprotein and the ligand are decoupled; wherein the crystalline-structuresimilarity prediction is used to determine the legitimacy of the one ormore bioactivity predictions; wherein the graph-based neural network ofthe protein and the graph-based neural network of the ligand are basedon one or more transformer convolution classifiers; wherein the one ormore outputs are used with a loss function to produce a trained modelfor bioactivity prediction; wherein the machine learning model is atransformer convolution classifier; further comprising an output of athree-dimensional visualization of the one or more protein-ligand pairs;wherein the three-dimensional visualization comprises features ofmolecular interaction properties.

BRIEF DESCRIPTION OF THE DRAWING FIGURES

The accompanying drawings illustrate several aspects and, together withthe description, serve to explain the principles of the inventionaccording to the aspects. It will be appreciated by one skilled in theart that the particular arrangements illustrated in the drawings aremerely exemplary, and are not to be considered as limiting of the scopeof the invention or the claims herein in any way.

FIG. 1 is a block diagram illustrating an exemplary overall systemarchitecture for a pharmaceutical research system.

FIG. 2 is a block diagram illustrating an exemplary system architecturefor an embodiment of a pharmaceutical research system utilizing combinedgraph-based and sequence-based prediction of molecule bioactivity.

FIG. 3 is a relational diagram illustrating several types of informationthat may be included in a knowledge graph for a pharmaceutical researchsystem and exemplary relations between those types of information.

FIG. 4 is a diagram illustrating the conceptual layering of differenttypes of information in a knowledge graph.

FIG. 5 is a relational diagram illustrating the use of a knowledge graphto predict usefulness of a molecule in treating a disease.

FIG. 6 is a diagram illustrating an exemplary process for combiningvarious types of information into a knowledge graph suitable for apharmaceutical research system.

FIG. 7 is a diagram illustrating an exemplary graph-based representationof molecules as simple relationships between atoms using a matrix ofadjacencies.

FIG. 8 is a diagram illustrating an exemplary graph-based representationof molecules as relationships between atoms using a matrix ofadjacencies wherein the type bonds are distinguished.

FIG. 9 is a diagram illustrating an exemplary graph-based representationof molecules as relationships between atoms using a matrix ofadjacencies using SMILES string encoding and one-hot vectors indicatingthe types of bonds between atoms.

FIG. 10 is a diagram illustrating an exemplary architecture forprediction of molecule bioactivity using concatenation of outputs from agraph-based neural network which analyzes molecule structure and asequence-based neural network which analyzes protein structure.

FIGS. 11A and 11B illustrates an exemplary implementation of anarchitecture for prediction of molecule bioactivity using concatenationof outputs from a graph-based neural network which analyzes moleculestructure and a sequence-based neural network which analyzes proteinstructure.

FIG. 12 illustrates an exemplary implementation of the moleculeattention assignment aspect of an architecture for prediction ofmolecule bioactivity using concatenation of outputs from a graph-basedneural network which analyzes molecule structure and a sequence-basedneural network which analyzes protein structure.

FIG. 13 is a diagram illustrating an exemplary architecture forprediction of molecule bioactivity using concatenation of outputs from agraph-based neural network and an attention-based transformer.

FIG. 14 is a flow diagram illustrating an exemplary method for activeexample generation.

FIG. 15 is a flow diagram illustrating an exemplary method for activeexample generation using a graph-based approach.

FIG. 16 is a flow diagram illustrating an exemplary method for activeexample generation using a 3D CNN approach.

FIG. 17 is a diagram illustrating the training of an autoencoder of a 3DCNN for active example generation.

FIG. 18 is a diagram illustrating the interfacing of the decoder to the3D-CNN bioactivity prediction model.

FIG. 19 is a diagram illustrating molecule encodings in latent space.

FIG. 20 is a block diagram of an overall model architecture of a systemfor de novo drug discovery according to one embodiment.

FIG. 21 is a block diagram of a model architecture of a MPNN encoder forde novo drug discovery according to one embodiment.

FIG. 22 is a block diagram of a model architecture of a Sampling modulefor de novo drug discovery according to one embodiment.

FIG. 23 is a block diagram of a model architecture of a decoder for denovo drug discovery according to one embodiment.

FIG. 24 is a block diagram of a model architecture for reinforcementlearning for de novo drug discovery according to one embodiment.

FIG. 25 is a block diagram of a model architecture of an autoregressivedecoder for de novo drug discovery according to one embodiment.

FIG. 26 is a block diagram of an exemplary system architecture for a 3DBioactivity platform.

FIG. 27 is a block diagram of an exemplary model architecture for a 3DBioactivity platform.

FIG. 28 is a flow diagram illustrating an exemplary method forclassifying protein-ligand pairs using a 3D Bioactivity platform.

FIG. 29 is a flow diagram illustrating an exemplary method forgenerating data for use in training a 3D-CNN used by a 3D Bioactivityplatform.

FIG. 30 is a block diagram of an exemplary system architecture for aPoint-Cloud Bioactivity platform.

FIG. 31 is a block diagram of an exemplary model architecture for aPoint-Cloud Bioactivity platform.

FIG. 32 is a flow diagram illustrating an exemplary method forclassifying protein-ligand pairs using a Point-Cloud Bioactivityplatform.

FIG. 33 is a block diagram illustrating an exemplary point-basedvisualization.

FIG. 34 is a diagram of exemplary pseudocode for implementing apoint-cloud based machine learning architecture.

FIG. 35 is a block diagram illustrating an exemplary hardwarearchitecture of a computing device.

FIG. 36 is a block diagram illustrating an exemplary logicalarchitecture for a client device.

FIG. 37 is a block diagram showing an exemplary architecturalarrangement of clients, servers, and external services.

FIG. 38 is another block diagram illustrating an exemplary hardwarearchitecture of a computing device.

DETAILED DESCRIPTION

Accordingly, the inventor has conceived and reduced to practice, asystem and method that predicts whether a given protein-ligand pair isactive or inactive, the ground-truth protein-ligand pair crystallinestructure similarity, and an associated bioactivity value. The systemand method further produce 3-D visualizations of previously unknownprotein-ligand pairs that show directly the importance assigned toprotein-ligand interactions, the positive/negative-ness of thesaliencies, and magnitude. Furthermore, the system and method makeenhancements in the art by accurately predicting protein-ligand pairbioactivity from decoupled models, removing the need for dockingsimulations, as well as restricting attention of the machine learningbetween protein and ligand atoms only.

One or more different aspects may be described in the presentapplication. Further, for one or more of the aspects described herein,numerous alternative arrangements may be described; it should beappreciated that these are presented for illustrative purposes only andare not limiting of the aspects contained herein or the claims presentedherein in any way. One or more of the arrangements may be widelyapplicable to numerous aspects, as may be readily apparent from thedisclosure. In general, arrangements are described in sufficient detailto enable those skilled in the art to practice one or more of theaspects, and it should be appreciated that other arrangements may beutilized and that structural, logical, software, electrical and otherchanges may be made without departing from the scope of the particularaspects. Particular features of one or more of the aspects describedherein may be described with reference to one or more particular aspectsor figures that form a part of the present disclosure, and in which areshown, by way of illustration, specific arrangements of one or more ofthe aspects. It should be appreciated, however, that such features arenot limited to usage in the one or more particular aspects or figureswith reference to which they are described. The present disclosure isneither a literal description of all arrangements of one or more of theaspects nor a listing of features of one or more of the aspects thatmust be present in all arrangements.

Headings of sections provided in this patent application and the titleof this patent application are for convenience only, and are not to betaken as limiting the disclosure in any way.

Devices that are in communication with each other need not be incontinuous communication with each other, unless expressly specifiedotherwise. In addition, devices that are in communication with eachother may communicate directly or indirectly through one or morecommunication means or intermediaries, logical or physical.

A description of an aspect with several components in communication witheach other does not imply that all such components are required. To thecontrary, a variety of optional components may be described toillustrate a wide variety of possible aspects and in order to more fullyillustrate one or more aspects. Similarly, although process steps,method steps, algorithms or the like may be described in a sequentialorder, such processes, methods and algorithms may generally beconfigured to work in alternate orders, unless specifically stated tothe contrary. In other words, any sequence or order of steps that may bedescribed in this patent application does not, in and of itself,indicate a requirement that the steps be performed in that order. Thesteps of described processes may be performed in any order practical.Further, some steps may be performed simultaneously despite beingdescribed or implied as occurring non-simultaneously (e.g., because onestep is described after the other step). Moreover, the illustration of aprocess by its depiction in a drawing does not imply that theillustrated process is exclusive of other variations and modificationsthereto, does not imply that the illustrated process or any of its stepsare necessary to one or more of the aspects, and does not imply that theillustrated process is preferred. Also, steps are generally describedonce per aspect, but this does not mean they must occur once, or thatthey may only occur once each time a process, method, or algorithm iscarried out or executed. Some steps may be omitted in some aspects orsome occurrences, or some steps may be executed more than once in agiven aspect or occurrence.

When a single device or article is described herein, it will be readilyapparent that more than one device or article may be used in place of asingle device or article. Similarly, where more than one device orarticle is described herein, it will be readily apparent that a singledevice or article may be used in place of the more than one device orarticle.

The functionality or the features of a device may be alternativelyembodied by one or more other devices that are not explicitly describedas having such functionality or features. Thus, other aspects need notinclude the device itself.

Techniques and mechanisms described or referenced herein will sometimesbe described in singular form for clarity. However, it should beappreciated that particular aspects may include multiple iterations of atechnique or multiple instantiations of a mechanism unless notedotherwise. Process descriptions or blocks in figures should beunderstood as representing modules, segments, or portions of code whichinclude one or more executable instructions for implementing specificlogical functions or steps in the process. Alternate implementations areincluded within the scope of various aspects in which, for example,functions may be executed out of order from that shown or discussed,including substantially concurrently or in reverse order, depending onthe functionality involved, as would be understood by those havingordinary skill in the art.

Definitions

“Bioactivity” as used herein means the physiological effects of amolecule on an organism (i.e., living organism, biological matter).

“Docking” as used herein means a method which predicts the orientationof one molecule to a second when bound to each other to form a stablecomplex. Knowledge of the preferred orientation in turn may be used topredict the strength of association or binding affinity between twomolecules.

“Edges” as used herein means connections between nodes or vertices in adata structure. In graphs, an arbitrary number of edges may be assignedto any node or vertex, each edge representing a relationship to itselfor any other node or vertex. Edges may also comprise value, conditions,or other information, such as edge weights or probabilities.

“FASTA” as used herein means any version of the FASTA family (e.g.,FASTA, FASTP, FASTA, etc.) of chemical notations for describingnucleotide sequences or amino acid (protein) sequences using text (e.g.,ASCII) strings.

“Force field” as used herein means a collection of equations andassociated constants designed to reproduce molecular geometry andselected properties of tested structures. In molecular dynamics amolecule is described as a series of charged points (atoms) linked bysprings (bonds).

“Ligand” as used herein means a substance that forms a complex with abiomolecule to serve a biological purpose. In protein-ligand binding,the ligand is usually a molecule which produces a signal by binding to asite on a target protein. Ligand binding to a receptor protein altersthe conformation by affecting the three-dimensional shape orientation.The conformation of a receptor protein composes the functional state.Ligands comprise substrates, inhibitors, activators, signaling lipids,and neurotransmitters.

“Nodes” and “Vertices” are used herein interchangeably to mean a unit ofa data structure comprising a value, condition, or other information.Nodes and vertices may be arranged in lists, trees, graphs, and otherforms of data structures. In graphs, nodes and vertices may be connectedto an arbitrary number of edges, which represent relationships betweenthe nodes or vertices. As the context requires, the term “node” may alsorefer to a node of a neural network (also referred to as a neuron) whichis analogous to a graph node in that it is a point of informationconnected to other points of information through edges.

“Pocket” or “Protein binding pocket” as used herein means a cavity(i.e., receptor, binding site) on the surface or in the interior of aprotein that possesses suitable properties for binding a ligand. The setof amino acid residues around a binding pocket determines itsphysicochemical characteristics and, together with its shape andlocation in a protein, defines its functionality.

“Pose” as used herein means a molecule within a protein binding sitearranged in a certain conformation.

“Proteins” as used herein means large biomolecules, or macromolecules,consisting of one or more long chains of amino acid residues. Proteinsperform a vast array of functions within organisms, including catalyzingmetabolic reactions, DNA replication, responding to stimuli, providingstructure to cells and organisms, and transporting molecules from onelocation to another. Proteins differ from one another primarily in theirsequence of amino acids, which is dictated by the nucleotide sequence oftheir genes, and which usually results in protein folding into aspecific 3D structure that determines its activity.

“SMILES” as used herein means any version of the “simplifiedmolecular-input line-entry system,” which is form of chemical notationfor describing the structure of molecules using short text (e.g., ASCII)strings.

Conceptual Architecture

FIG. 1 is a block diagram illustrating an exemplary overall systemarchitecture for a pharmaceutical research system. The exemplaryarchitecture comprises a data platform 110 which provides the corefunctionality of the system, plus one or more modules that utilize thedata platform 110 to provide functionality in specific areas ofresearch, in this case a bioactivity module 120, a de novo liganddiscovery module 130, a clinical trials module 140, and an absorption,distribution, metabolism, excretion, and toxicity (ADMET) module 150.

The data platform 110 in this embodiment comprises a knowledge graph111, an exploratory drug analysis (EDA) interface 112, a data analysisengine 113, a data extraction engine 114, and web crawler/databasecrawler 115. The crawler 115 searches for and retrieves medicalinformation such as published medical literature, clinical trials,dissertations, conference papers, and databases of known pharmaceuticalsand their effects. The crawler 115 feeds the medical information to adata extraction engine 114, which uses natural language processingtechniques to extract and classify information contained in the medicalliterature such as indications of which molecules interact with whichproteins and what physiological effects have been observed. Using thedata extracted by the data extraction engine 114, a knowledge graph 111is constructed comprising vertices (also called nodes) representingpieces of knowledge gleaned from the data and edges representingrelationships between those pieces of knowledge. As a very briefexample, it may be that one journal article suggests that a particularmolecule is useful in treating a given disease, and another journalarticle suggests that a different molecule is useful for treating thesame disease. The two molecules and the disease may be represented asvertices in the graph, and the relationships among them may berepresented as edges between the vertices. The EDA interface 112 is auser interface through which pharmaceutical research may be performed bymaking queries and receiving responses. The queries are sent to a dataanalysis engine 113 which uses the knowledge graph 111 to determine aresponse, which is then provided to the user through the EDA interface112. In some embodiments, the data analysis engine 113 comprises one ormore graph-based neural networks (graph neural networks, or GNNs) toprocess the information contained in the knowledge graph 111 todetermine a response to the user's query. As an example, the user maysubmit a query for identification of molecules likely to have similarbioactivity to a molecule with known bioactivity. The data analysisengine 113 may process the knowledge graph 111 through a GNN to identifysuch molecules based on the information and relationships in theknowledge graph 111.

The bioactivity module 120 utilizes the data platform 110 to analyze andpredict the bioactivity of molecules based on protein 121 and ligand 122similarities and known or suspected protein 121 and ligand 122compatibilities. The module utilizes the knowledge graph 111 and dataanalysis engine 113 capabilities of the data platform 110, and in oneembodiment is configured to predict the bioactivity of a molecule basedon and their known or suspected compatibilities with certaincombinations of proteins 121 and ligands 122. Thus, using thebioactivity module 120, users can research molecules by entering queriesthrough the EDA interface 112, and obtaining using predictions ofbioactivity based on known or suspected bioactivity of similar moleculesand their compatibilities with certain protein 121 and ligand 122combinations.

The de novo ligand discovery module 130 utilizes the data platform 110to identify ligands and their properties through data enrichment andinterpolation/perturbation. The module utilizes the knowledge graph 111and data analysis engine 113 capabilities of the data platform 110, andin one embodiment is configured to identify ligands with certainproperties based on three dimensional (3D) models 131 of known ligandsand differentials of atom positions 132 in the latent space of themodels after encoding by a 3D convolutional neural network (3D CNN),which is part of the data analysis engine 113. In one embodiment, the 3Dmodel comprises a voxel image (volumetric, three dimensional pixelimage) of the ligand. In cases where enrichment data is available,ligands may be identified by enriching the SMILES string for a ligandwith information about possible atom configurations of the ligand andconverting the enriched information into a plurality of 3D models of theatom. In cases where insufficient enrichment information is available,one possible configuration of the atoms of the ligand may be selected,and other configurations may be generated by interpolation orperturbation of the original configuration in the latent space afterprocessing the 3D model through the CNN. In either case, the 3D modelsof the ligands are processed through a CNN, and a gradient descent isapplied to changes in atom configuration in the latent space to identifynew ligands with properties similar to the modeled ligands. Thus, usingthe de novo ligand discovery module 130, users can identify new ligandswith properties similar to those of modeled ligands by entering queriesthrough the EDA interface 112.

The clinical trials module 140 utilizes the data platform 110 to analyze141 and optimize 142 the knowledge contained in or derived from clinicaltrials. The module utilizes the knowledge graph 111 and data analysisengine 113 capabilities of the data platform 110, and in one embodimentis configured to return clinical trials similar to a specified clinicaltrial in one or more aspects (e.g., proteins and ligands studied,methodology, results, etc.) based on semantic clustering within theknowledge graph 111. Thus, using the clinical trials module 140, userscan research a large database of clinical trials based on aspects ofinterest by entering queries through the EDA interface 112.

The ADMET module 150 utilizes the data platform 110 to predict 151absorption, distribution, metabolism, excretion, and toxicitycharacteristics of ligands based on ADMET databases. The module utilizesthe knowledge graph 111 and data analysis engine 113 capabilities of thedata platform 110, and in one embodiment is configured to return ligandswith characteristics similar to, or dissimilar to, a specified ligand inone or more respects (e.g., a ligand with similar absorption andmetabolism characteristics, but dissimilar toxicity characteristics)based on semantic clustering within the knowledge graph 111. Thus, usingthe ADMET module 150, users can research a large ADMET database based onaspects of interest by entering queries through the EDA interface 112.

FIG. 2 is a block diagram illustrating an exemplary system architecturefor an embodiment of a pharmaceutical research system utilizing combinedgraph-based and sequence-based prediction of molecule bioactivity. Inthis embodiment, the system comprises a data curation platform 210, adata analysis engine 220 comprising a training stage 230 and an analysisstage 240, and an exploratory drug analysis interface 250. The knowledgegraph 215 does not refer to a graph representation of the inputs to themodel, but to a relational structure of the data in the database itself.The knowledge graph 215 itself is not used as input.

In the data curation platform 210, a web crawler/database crawler 211 isconfigured to search for and download medical information materialsincluding, but not limited to, archives of published medical literaturesuch as MEDLINE and PubMed, archives of clinical trial databases such asthe U.S. National Library of Medicine's ClinicalTrials.gov database andthe World Health Organization International Clinical Trials RegistryPlatform (ICTRP), archives of published dissertations and theses such asthe Networked Digital Library of These and Dissertations (NDLTD),archives of grey literature such as the Grey Literature Report, and newsreports, conference papers, and individual journals. As the medicalinformation is downloaded, it is fed to a data extraction engine 212which may perform a series of operations to extract data from themedical information materials. For example, the data extraction engine212 may first determine a format of each of the materials received(e.g., text, PDFs, images), and perform conversions of materials not ina machine-readable or extractable format (e.g., performing opticalcharacter recognition (OCR) on PDFs and images to extract any textcontained therein). Once the text has been extracted from the materials,natural language processing (NLP) techniques may be used to extractuseful information from the materials for use in analysis by machinelearning algorithms. For example, semantic analysis may be performed onthe text to determine a context of each piece of medical informationmaterial such as the field of research, the particular pharmaceuticalsstudied, results of the study, etc. Of particular importance isrecognition of standardized biochemistry naming conventions including,but not limited to, stock nomenclature, International Union of Pure andApplied Chemistry (IUPAC) conventions, and simplified molecular-inputline-entry system (SMILES) and FASTA text-based moleculerepresentations. The data extraction engine 212 feeds the extracted datato a knowledge graph constructor 213, which constructs a knowledge graph215 based on the information in the data, representing informationalentities (e.g., proteins, molecules, diseases, study results, people) asvertices of a graph and relationships between the entities as edges ofthe graph. Biochemical databases 214 or similar sources of informationmay be used to supplement the graph with known properties of proteins,molecules, physiological effects, etc. Separately from the knowledgegraph 215, vector representations of proteins, molecules, interactions,and other information may be represented as vectors 216, which mayeither be extracted from the knowledge graph 215 or may be createddirectly from data received from the data extraction engine 212. Thelink between the knowledge graph 215 and the data analysis engine 220 ismerely an exemplary abstraction. The knowledge graph 215 does not feedinto the models directly but rather the data contained in a knowledgegraph structured database is used to train the models. The sameexemplary abstraction applies between the vector extraction andembedding 216 and the data analysis engine 220.

The data analysis engine 220 utilizes the information gathered,organized, and stored in the data curation platform 210 to train machinelearning algorithms at a training stage 230 and conduct analyses inresponse to queries and return results based on the analyses at ananalysis stage 240. The training stage 230 and analysis stage 240 areidentical, whereas the analysis stage 240 has already completedtraining. In this embodiment, the data analysis engine 220 comprises adual analysis system which combines the outputs of a trained graph-basedmachine learning algorithm 241 with the outputs of a trainedsequence-based machine learning algorithm 242. The trained graph-basedmachine learning algorithm 241 may be any type of algorithm configuredto analyze graph-based data, such as graph traversal algorithms,clustering algorithms, or graph neural networks.

At the training stage 230, information from the knowledge graph 215 isextracted to provide training data in the form of graph-basedrepresentations of molecules and the known or suspected bioactivity ofthose molecules with certain proteins. The graph-based representations,or 3D representations in the 3D case, of the molecules and proteins andtheir associated bioactivities are used as training input data to agraph-based machine learning algorithm 231, resulting in a graph-basedmachine learning output 233 comprising vector representations of thecharacteristics of molecules and their bioactivities with certainproteins. Simultaneously, a sequence-based machine learning algorithm islikewise trained, but using information extracted 216 from the knowledgegraph 215 in the form of vector representations of protein segments andthe known or suspected bioactivity of those protein segments withcertain molecules. The vector representations of the protein segmentsand their associated bioactivities are used to train the concatenatedoutputs 235, as well as the machine learning algorithms 231, 232, 233,234. In this embodiment, the graph-based machine learning outputs 233and the sequence-based machine learning outputs 234 are concatenated toproduce a concatenated output 235, which serves to strengthen thelearning information from each of the separate machine learningalgorithms. In this and other embodiments, the concatenated output maybe used to re-train both machine learning algorithms 233, 234 to furtherrefine the predictive abilities of the algorithms.

At the analysis stage, a query in the form of a target ligand 244 and atarget protein 245 are entered using an exploratory drug analysis (EDA)interface 250. The target ligand 244 is processed through the trainedgraph-based machine learning algorithm 241 which, based on its training,produces an output comprising a vector representation of the likelihoodof interaction of the target ligand 244 with certain proteins and thelikelihood of the bioactivity resulting from the interactions.Similarly, the target protein 245 is processed through the trainedsequence-based machine learning algorithm 242 which, based on itstraining, produces an output comprising a vector representation of thelikelihood of interaction of the target protein 245 with certain ligandsand the likelihood of the bioactivity resulting from the interactions.The results may be concatenated 243 to strengthen the likelihoodinformation from each of the separate trained machine learningalgorithms 241, 242.

FIG. 3 is a relational diagram 300 illustrating several types ofinformation that may be included in a knowledge graph for apharmaceutical research system and exemplary relations between thosetypes of information. In this example, six types of information areshown with indications of certain relevant relationships andinteractions that may be represented in a knowledge graph containingthese types of information. The six types of information in this exampleare chosen to be of particular relevance to pharmaceutical research, andin particular to the analysis of, and prediction of, biochemicalproperties of proteins and ligands as they relate to disease. Proteins305 and molecules (ligands) 306 are the primary types of information, astheir biochemical relationships and properties determine effects ondiseases 303. Genetic information 304 will have an influence on theproduction of specific proteins 305 and the association with certaindiseases 303. Assays 301 will provide information about the quality andquantity relationships of proteins 350 and molecules 306, which providessupporting data for clinical trials 302 and for functional activityrelationships with certain diseases 303. Clinical trials 302 provideconfirmation of physiological effects and suggestion of biologicalpathways related to diseases. While this simplified diagram does notpurport to show all types of data that may be included or allrelationships that may be relevant, it does show certain important typesof data and major relevancies that may be included in a knowledge graphto be used for a pharmaceutical research system.

FIG. 4 is a diagram illustrating the conceptual layering 400 ofdifferent types of information in a knowledge graph. While knowledgegraphs are not necessarily constructed in layers, each type ofinformation included in a knowledge graph may be conceived as a layer ofinformation in the knowledge graph and each layer may be analyzed todetermine clustering and other relationships within the layer. Forexample, proceeding with the types of information shown in FIG. 3, theknowledge graph can be conceived of as having layers for clinical trials401, diseases 402, genetic information 403, assays 404, molecules 405,etc. Relationships such as clustering can be seen at each layer, and canbe analyzed separately, if necessary. However, in a knowledge graph,connections between the information at each layer are made andrelationships between the information at each layer can be analyzed.

FIG. 5 is a relational diagram illustrating the use of a knowledge graphto predict usefulness of a molecule in treating a disease 500. In thisexample, a first molecule 505 is known to bind with a first protein 507which is produced from a first set of genetic information 508. Aclinical trial 501 confirmed that the first molecule 505 is effective intreating a disease 504. The clinical trial 501 used information fromassays 503 that were performed on the first molecule 505 and the firstprotein 507. A query has been submitted to the system to identify asecond molecule 506 that may also be effective in treating 511 the samedisease 504, but with fewer side effects. Using a knowledge graphcontaining the types of information shown in FIG. 3, and a graph-basedmachine learning algorithm, the system identifies a second molecule 506that binds with a second protein 509 which is produced from a second setof genetic information 510. The system determines a number ofsimilarities and relationships between the first molecule 505 and thesecond molecule 506, including that the first molecule 505 is chemicallysimilar to the second molecule 506, the protein 507 with which the firstmolecule 505 binds is related to the second protein 509 with which thesecond molecule 506 binds, and the genetic information (DNA strands) 508that produces the first protein 507 are similar to the geneticinformation 510 that produces the second protein 509. Thus, the systemdetermines that the second molecule 506 is likely to have a similareffect on the disease 504 as the first molecule 505. Further, the systemidentifies a second clinical trial 502 that suggests that the secondmolecule 506 has lesser side effects than the first molecule 505. As thesecond molecule 506 meets the query criteria, it is returned as aresponse to the query.

FIG. 6 is a diagram illustrating an exemplary process 600 for combiningvarious types of information into a knowledge graph suitable for apharmaceutical research system. As data is received from a dataextraction engine in each of several categories of data (in thisexample, six categories: assays 301, clinical trials 302, diseases 303,genetic information 304, proteins 305, and molecules 306) nodes areassigned to each entity identified in each category and attributes ofthe entity are assigned to the node 601 a-f. Attributes of thenodes/entity are information describing the characteristics of thenodes/entity. For example, in some embodiments, attributes of nodesrelated to molecules are in the form of an adjacency matrix whichrepresents the molecule as relationships between the atoms of themolecule. After nodes have been assigned to all identified entities 601a-f, the relationships between entities are assigned, both within thecategory of knowledge and between all other categories of knowledge 602a-f. As a simple example of the process, assume that a certain molecule306 is identified during data extraction. A node is created for themolecule and attributes are assigned to the molecule/node in the form ofan adjacency matrix representing the molecule as a series ofrelationships between the atoms of the molecule. Through a series ofassays 301 and clinical studies 302, it is known that the molecule bindswith a particular protein 305, and is effective in treating a certaindisease 303, to which individuals with certain genetic information 304are susceptible. Nodes are assigned to each of the assays 301, clinicaltrials 302, diseases 303, proteins 305, and genetic information 304identified as being associated with the molecule, and edges areestablished between the nodes reflecting the relevant relationships suchas: the molecule binds with the protein, the genetic information isassociated with the disease, the clinical trials indicate that thedisease is treatable by the molecule, and so on.

FIG. 7 is a diagram illustrating an exemplary graph-based representationof molecules as simple relationships between atoms using a matrix ofadjacencies 700, wherein atoms are represented as nodes and bondsbetween the atoms are represented as edges. Representation of moleculesas a graph is useful because it provides a molecular structure which canbe processed by graph-based machine learning algorithms like GNNs.Further, the graph-based representation of a molecule can be stated interms of two matrices, one for the node features (e.g., type of atom andits available bonds) and one for the edges (i.e., the bonds between theatoms). The combination of the nodes (atoms) and edges (bonds)represents the molecule. Each molecule represented in the matrixcomprises a dimensionality and features that describe the type of bondbetween the atoms. According to one embodiment, all bonds within thegraph hold the same value, e.g., 1. However, in other embodiments, bondsmay be differentiated such as hydrogen bonds having a value of 3, or byhaving the bond feature dimension exist in each cell.

In this example, a simple hydrogen cyanide molecule is shown as agraph-based representation 710. A hydrogen cyanide molecule consists ofthree atoms, a hydrogen atom 711, a carbon atom 712, and a nitrogen atom713. Its standard chemical formula is HCN. Each atom in the molecule isshown as a node of a graph. The hydrogen atom 711 is represented as anode with node features 721 comprising the atom type (hydrogen) and thenumber of bonds available (one). The carbon atom 712 is represented as anode with node features 722 comprising the atom type (carbon) and thenumber of bonds available (four). The nitrogen atom 713 is representedas a node with node features 723 comprising the atom type (nitrogen) andthe number of bonds available (three). The node features 721, 722, 723may each be stated in the form of a matrix.

The relationships between the atoms in the molecule are defined by theadjacency matrix 730. The top row of the adjacency matrix 731 shows allof the atoms in the molecule, and the left column of the matrix 732shows a list of all possible atoms that can be represented by the matrixfor a given set of molecules. In this example, the top row 731 and leftcolumn 732 contain the same list of atoms, but in cases where multiplemolecules are being represented in the system, the left column maycontain other atoms not contained in the particular molecule beingrepresented. The matrix shows, for example, that the hydrogen atom 711is connected to the carbon atom 712 (a “1” at the intersection of therows and columns for H and C) and that the carbon atom 712 is connectedto the nitrogen atom 713 (a “1” at the intersection of the rows andcolumns for C and N). In this example, each atom is also self-referenced(a “1” at the intersection of the rows and columns for H and H, C and C,and N and N), but in some embodiments, the self-referencing may beeliminated. In some embodiments, the rows and columns may be transposed(not relevant where the matrix is symmetrical, but relevant where it isnot).

FIG. 8 is a diagram illustrating an exemplary graph-based representationof molecules as relationships between atoms using a matrix ofadjacencies 800, wherein atoms are represented as nodes and bondsbetween the atoms are represented as edges, and wherein the type andnumber of bonds are distinguished. Representation of molecules as agraph is useful because it provides a molecular structure which can beprocessed by graph-based machine learning algorithms like GNNs. Further,the graph-based representation of a molecule can be stated in terms oftwo matrices, one for the node features (e.g., type of atom and itsavailable bonds) and one for the edges (i.e., the bonds between theatoms). The combination of the nodes (atoms) and edges (bonds)represents the molecule.

In this example, a simple hydrogen cyanide molecule is shown as agraph-based representation 810. A hydrogen cyanide molecule consists ofthree atoms, a hydrogen atom 811, a carbon atom 812, and a nitrogen atom813. Its standard chemical formula is HCN. Each atom in the molecule isshown as a node of a graph. The hydrogen atom 811 is represented as anode with node features 821 comprising the atom type (hydrogen) and thenumber of bonds available (one). The carbon atom 812 is represented as anode with node features 822 comprising the atom type (carbon) and thenumber of bonds available (four). The nitrogen atom 813 is representedas a node with node features 823 comprising the atom type (nitrogen) andthe number of bonds available (three). The node features 821, 822, 823may each be stated in the form of a matrix.

The relationships between the atoms in the molecule are defined by theadjacency matrix 830. The top row of the adjacency matrix 831 shows allof the atoms in the molecule, and the left column of the matrix 832shows a list of all possible atoms that can be represented by the matrixfor a given set of molecules. In this example, the top row 831 and leftcolumn 832 contain the same list of atoms, but in cases where multiplemolecules are being represented in the system, the left column maycontain other atoms not contained in the particular molecule beingrepresented. The matrix shows, for example, that the hydrogen atom 811is connected to the carbon atom 812 (a “1” at the intersection of therows and columns for H and C) and that the carbon atom 812 is connectedto the nitrogen atom 813 (a “3” at the intersection of the rows andcolumns for C and N). In this example, the number of bonds between atomsis represented by the digit in the cell of the matrix. For example, a 1represents a single bond, whereas a 3 represents a triple bond. In thisexample, each atom is also self-referenced (a “1” at the intersection ofthe rows and columns for H and H, C and C, and N and N), but in someembodiments, the self-referencing may be eliminated. In someembodiments, the rows and columns may be transposed (not relevant wherethe matrix is symmetrical, but relevant where it is not).

FIG. 9 is a diagram illustrating an exemplary graph-based representationof molecules as relationships between atoms using a matrix ofadjacencies 900, wherein atoms are represented as nodes and bondsbetween the atoms are represented as edges, and wherein the matrix ofadjacencies uses a SMILES string encoding of the molecule and one-hotvector representations of the type of bonds between atoms in themolecule. Representation of molecules as a graph is useful because itprovides a molecular structure which can be processed by graph-basedmachine learning algorithms like GNNs. Further, the graph-basedrepresentation of a molecule can be stated in terms of two matrices, onefor the node features (e.g., type of atom and its available bonds) andone for the edges (i.e., the bonds between the atoms). The combinationof the nodes (atoms) and edges (bonds) represents the molecule.

In this example, a simple hydrogen cyanide molecule is shown as agraph-based representation 910. A hydrogen cyanide molecule consists ofthree atoms, a hydrogen atom 911, a carbon atom 912, and a nitrogen atom913. Its SMILES representation text string is [H]C#N, with the bracketsaround the H indicating an element other than an organic element, andthe # representing a triple bond between the C and N. Each atom in themolecule is shown as a node of a graph. The hydrogen atom 911 isrepresented as a node with node features 921 comprising the atom type(hydrogen) and the number of bonds available (one). The carbon atom 912is represented as a node with node features 922 comprising the atom type(carbon) and the number of bonds available (four). The nitrogen atom 913is represented as a node with node features 923 comprising the atom type(nitrogen) and the number of bonds available (three). The node features921, 922, 923 may each be stated in the form of a matrix 930.

In this example, the top row 931 and left column 932 contain the samelist of atoms, but in cases where multiple molecules are beingrepresented in the system, the left column may contain other atoms notcontained in the particular molecule being represented. The matrixshows, for example, that the hydrogen atom 811 is connected to thecarbon atom 812 with a single bond (the one-hot vector “(1,0,0)” at theintersection of the rows and columns for H and C) and that the carbonatom 812 is connected to the nitrogen atom 813 with a triple bond (theone-hot vector “(0,0,1)” at the intersection of the rows and columns forC and N). In this example, the number of bonds between atoms isrepresented by a one-hot vector in the cell of the matrix. For example,a 1 in the first dimension of the vector (1,0,0) represents a singlebond, whereas a 1 in the third dimension of the vector (0,0,1)represents a triple bond. In this example, self-referencing of atoms iseliminated, but self-referencing may be implemented in otherembodiments, or may be handled by assigning self-referencing at theattention assignment stage. In some embodiments, the rows and columnsmay be transposed (not relevant where the matrix is symmetrical, butrelevant where it is not).

FIG. 14 is a flow diagram illustrating an exemplary method for activeexample generation. According to a general methodology description,generating active examples (i.e., chemically valid ligand-receptorpairs) is performed by the first step of gathering known active examplesfrom databases, web-crawlers, and other sources previously described inpast figures 1401. Active examples may then be enriched to fill inmissing data, supplement, append or otherwise enhance the training data1402. A specific example of enrichment may be finding similar compoundswith the same properties as a target molecule or that responds to knownligands in the same fashion. With the enhanced training data (i.e.,enriched active examples) gathered, it is fed into a neural network (NN)1403. A consideration must be noted that many machine learningalgorithms exist, and that this method may work with many NN models orother machine learning algorithms and is not limited to the onesdisclosed herein.

The neural networks build a model from the training data. In the case ofusing an autoencoder (or a variational autoencoder), the encoder portionof the neural network reduces the dimensionality of the input molecules,learning a model from which the decoder portion recreates the inputmolecule. The significance of outputting the same molecule as the inputis that the decoder may then be used as a generative function for newmolecules. One aspect of a generative decoder module is that the learnedmodel (i.e., protein-ligand atom-features according to one embodiment)lies in a latent space 1404. Sampled areas of the latent space are theninterpolated and perturbed 1405 to alter the model such that new andunique latent examples 1406 may be discovered. Other ways to navigatethe latent space exist, Gaussian randomization as one example, that maybe used in other embodiments of the invention. Furthermore, libraries,other trained models, and processes exist that may assist in thevalidation of chemically viable latent examples within the whole of thelatent space; processing the candidate set of latent examples through abioactivity model, as one example 1407.

Regarding retrosynthesis for de novo drug design, two approaches aredescribed below. A first approach begins with preprocessing all theSMILES representations for reactants and products to convert tocanonical form (SMILES to Mol & Mol to SMILES through a cheminformaticstoolkit), remove duplicates & clean the data, augmenting SMILEequivalents via enumeration. Then, transformer models are used withmultiple attention heads and a k-beam search is set up. Further, themodels are conformed by optimizing on producing long-term reactants,ensuring the models are robust to different representations of amolecule, providing intrinsic recursion (using performers), andincluding further reagents such as catalysts and solvents.

A second approach begins with augmenting the transformer model with ahyper-graph approach. Starting with an initial node of the graph as thequery molecule and recursively: the molecule with highest upper-boundconfidence (UCB) score is selected (specifically, the UCB is adapted totrees generation UCT), the node is expanded (if this node is notterminal), and expansions from that node are simulated to recover areward. Rewards are backpropagated along the deque of selected nodes,and the process is repeated until convergence. Here UCB is used as aform of balancing exploration-exploitation, where X is the reward, n isthe number of times the parent node has been visited, j denotes thechild node index, and C_(p) (>0) is an exploration constant. In oneembodiment, the model may be constrained to a rewarding a node when itschildren are accessible, wherein other embodiments may use rewards suchas molecular synthesis score, Log P, synthesis cost, or others known inthe art.

${UCT} = {{\overset{\_}{X}}_{j} + {2C_{p}\sqrt{\frac{2\mspace{11mu}\ln\mspace{11mu} n}{n_{j}}}}}$

According to one aspect of the second approach, transformer models areoptimized so that they produce a molecule that can be formed withanother molecule. However, these models should be optimized with the aimof producing reactants which are going to recursively deconstruct intoaccessible molecules. Hence, adding reinforcement learning finetuning toforce the transformer model to not only produce reactants which areplausible but to produce reactants which lead to favorableretrosynthetic routes.

FIG. 15 is a flow diagram illustrating an exemplary method for activeexample generation using a graph-based approach. According to a firstpreferred embodiment of active example generation, where a graph-basedmethod is used, active molecules are input (via a WebApp according toone aspect) as SMILES representations 1501. This involves training anautoencoder to obtain a fixed-dimensional representation of SMILES andmay further be reused for the bioactivity model. Additionally, standardSMILES encoding fails to capture all pertinent information relating tothe atoms (e.g., bond length). Consequently, enumeration may be used toimprove the standard SMILES model where enumeration is an equivalent todata augmentation via rotation, therefore by having different SMILESrepresentations of the same molecule from different orientations themissing information is captured. Other enumeration methods may be usedwhere data is necessary but missing. The enumerated SMILES encoding usedmay comprise one-hot encodings of atom type, atom degree, valence,hybridization, and chirality as well as formal charge and number ofradical electrons. Bond types (single, double, triple, and aromatic),bond length, and bond conjugation with ring and stereo features are alsocaptured.

Enrichment of the input data may be performed by searching through datasets for similar compounds through specific tags (e.g., anti-viral)1502. Additionally, the enrichment process may be used if the trainingdata lacks any descriptive parameters, whereby databases, web-crawlers,and such may fill in the missing parameters 1502. Enrichment may alsooccur where data is sparse by interpolating between known molecules1503. This enriched training data is then captured in node and edgefeature matrices. Some embodiments may use matrices comprising a nodefeature matrix, N, of shape (No_Atoms, No_Features_Atom) and edgefeature (adjacency) tensor, A, of shape (No_Atoms, No_Atoms,No_Features_Bond). A reminder to the reader that a tensor's rank is itsmatrix dimensionality.

The next step is to pass examples through a variational autoencoder(VAE) together with a reinforcement learning component to build the fullmodel 1504 (See FIG. 20). The encoder of this embodiment consists of amessage passing neural network, which given node and edge features isdesigned to learn a hidden representation of a molecule (i.e., a readoutvector). This is done by continuously aggregating neighboring node andedge information through a process called message passing. The readoutvector is subsequently split into the mean and variance vectors whichserve and as the parameters of the posterior distribution from thesampling. The model may learn a latent distribution that governsmolecular properties and provide a decoder which can constructchemically valid molecules from samples of the prior 1505. Latentsamples are passed through a sequence of dense layers, after which thetwo different matrices (node feature matrix, N and edge feature tensor)are used to reconstruct the node feature and edge feature matrices.Keeping with the example described in the paragraph above, these twomatrices must have the shapes of (No Atoms, No Node Features) and (NoAtoms, No Atoms, No Edge Features) respectively. This may be enforced byusing a maximum number of allowed atoms to reconstruct. Further, anadditional entry for each of the encoded feature distributions may beallowed, which represents the possibility of No Atom/No Feature. Thenode and edge feature matrices are compared using an approximate graphmatching procedure which looks at atom types, bond types, atom-bond-atomtypes.

Reinforcement learning may be used in parallel to provide an additionalgradient signal, checking that decoded molecules are chemically validusing cheminformatics toolkits. In particular, samples from the priordistribution (N (0,1)) as well as posterior distribution (N (mean, std))are decoded 1506 and their validity is evaluated 1507. If thecheminformatics toolkit is non-differentiable, then a reward predictionnetwork (a separate MPNN encoder) that is trained to predict thevalidity of an input graph may be used. Together, these componentsprovide an end to end, fully differentiable framework for training.Other choices for data can be QM9, or any other database that isconsidered valid.

According to one aspect, in order to make use of more molecules,alternative reconstructability criteria may be used to ensure a chemicalsimilarity threshold instead of perfect reconstruction. For example,encoding and decoding several times and using a molecule if itsreconstruction has a chemical similarity above a certain threshold mayresult in a greater number of reconstructable molecules.

New molecules may also be generated via perturbation, wherein theencodings of the active molecules (i.e., the mean and log(sigma²)values) are taken and Gaussian noise is added to them. A sample from thenew (mean, log(sigma²)) values are taken and decoded to derive novelmolecules. An important hyperparameter is the magnitude of the Gaussiannoise that is added to latent vectors. It is also possible todynamically adjust the perturbation coefficient, for example, increasingit if the proportion of new molecules is low and decreasing itotherwise.

New molecules may also be generated via interpolation. To generate viainterpolation, two random reconstructable molecules are taken, computedtogether for an interpolation of their latent (mean, log(sigma²))representations with a random interpolation coefficient, and thendecoded to get a new molecule. Generative Adversarial Networks (GANs)excel at interpolation of high dimensional inputs (e.g., images).According to one aspect, the dimension of p(z) corresponds to thedimensionality of the manifold. A method for latent space shaping is asfollows: Converge a simple autoencoder on a large z, find the PrincipalComponent Analysis (PCA) which corresponds to the 95th percentile of the“explained variance”, and choose a z within that spectrum (i.e., if thefirst 17 components of the latent space to represent 95% of the data,choosing z of 24 is a good choice). Now, for high dimensional latentspaces with a Gaussian prior, most points lie within a hyper sphericalshell. This is typically the case in multi-dimensional gaussians. Tothat end, slerp (spherical linear interpolation) interpolation may beused between vectors v1 and v2. Therefore, interpolation is a direct wayto explore the space between active molecules.

FIG. 16 is a flow diagram illustrating an exemplary method for activeexample generation using a 3D CNN approach. According to an embodimentof active example generation, a 3-dimensional convolutional neuralnetwork (3D CNN) is used in which atom-type densities are reconstructedusing a sequence of 3D convolutional layers and dense layers. Since theoutput atom densities are fully differentiable with respect to thelatent space, a trained variational autoencoder (VAE) 1606 may connectto a bioactivity-prediction module 1604 comprising a trained 3D-CNNmodel with the same kind of atom densities (as output by theautoencoder) as the features, and then optimize the latent space withrespect to the bioactivity predictions against one or more receptors.After that, the optimal point in the latent space can be decoded into amolecule with the desired properties.

Three-dimensional coordinates of potential molecules 1601 are used asinputs to a neural network for 3D reconstruction in latent space 1603(the 3D models of molecules using volumetric pixels called voxels).Underfitting due to data sparsity may be prevented by optional smoothing1602 depending on the machine learning algorithm used. Existing moleculeexamples 1605 are used to train one or more autoencoders 1606 wherebythe output of the decoder is used to map atomic features such as atomdensity in latent space 1607 in the bioactivity model 1604, wherein thebioactivity model consists of a sequence of convolutional and fullyconnected layers. Backpropagation 1608 (or other gradient-aided search)is performed by searching the latent space for regions that optimize thebioactivities of choice thus arriving at a set of latent examples 1609.Decoding 1610 and ranking 1611 each candidate latent example producesthe most viable and best-fit to the initial desired parameters.

As an example, a VAE is trained on an enriched molecule data set untiloptimal reconstruction is achieved. The decoder of the VAE is used as aninput to a bioactivity model, wherein the VAE input is a small moleculeand the bioactivity module houses a large molecule, i.e., a protein. Thebehavior and interactions between the molecules are output from thebioactivity model to inform the latent space of the VAE.

FIG. 17 is a diagram illustrating the training of an autoencoder 1700 ofa 3D CNN for active example generation. In a second preferredembodiment, 3D coordinates of the atomic positions of molecules arereconstructed as smoothed (Gaussian blurring as one method) 3D models1702, 1705 alleviating the underfitting of encoder 1703 and 3D CNNdecoder 1704 models due to high data disparity. Wave representations1702, 1705 allow voxels to convey the same information as the 3Dstructures 1701, 1706. One exemplary embodiment uses PyTorch, anopen-source machine learning library used for applications such ascomputer vision and natural language processing, and is used toinitially train an autoencoder.

Autoencoders 1700 may also be implemented by other programming languagesand forks other than PyTorch. Additional embodiments may comprise acomplex pipeline involving Generative Adversarial Networks (GANs) and ahybrid between localized non-maximal suppression (NMS) and negativeGaussian sampling (NGS) may be used to perform the mapping of smoothedatom densities to formats used to reconstruct the molecular graph.Furthermore, training autoencoders 1700 on generating active examples bydeconvolution is improved by using a GPU (Graphical Processing Unit)rather than a CPU (Central Processing Unit). Using the embodiments asdescribed above, grants input atom densities to generate detaileddeconvolutions by varying noise power spectral density andsignal-to-noise ratios.

As a detailed example, the generation may be done in the followingsteps, using any number of programming languages but is described hereusing the structure of Python, and by creating various functions (wherefunctions are subsets of code that may be called upon to perform anaction). The model is initialized with a trained autoencoder and adataset of active molecules. The latent representations of the activedataset (or their distributions, in the case a variational autoencoderis used) are computed, by learning the latent space, which may compriseone function. This function may also store the statistics of the activedataset reconstructions, to compare with the statistics of the generateddata later. A function which generates a set number of datapoints usingthe chosen generation method is also employed using a flag method withinthe class instance may control the generation method (e.g. “perturb”,“interp”). Additional parameters for the methods, e.g. the perturbationstrength, may be also controlled using instance variables. Anotherfunction may be programmed that decodes the generated latent vectors andcomputes statistics of the generated datasets. These statistics includethe validity (percentage of the samples which are valid molecules),novelty (percentage of molecules distinct from the active dataset), anduniqueness (percentage of distinct molecules) of the dataset, as well asthe molecular properties, specified in a separate function that computesthe properties. Molecular properties may be added or removed to thisfunction at will, without any changes to the rest of the code:summarized statistics and plots are inferred from the molecularproperties dictionary. Results may then be summarized in two ways: byprinting out the summary of the distributions and generating plotscomparing the molecular properties as defined in the computer propertiesfunction of the active and generated distributions.

All variables, functions, and preferences are only presented asexemplary and are not to be considered limiting to the invention in anyway. Many avenues of training autoencoders or variational autoencodersare known to those in the art by which any number of programminglanguages, data structures, classes, and functions may be alternativelyswitched out depending on implementation and desired use.

FIG. 18 is a diagram illustrating the interfacing of the decoder to the3D-CNN bioactivity prediction model 1800. During training of the neuralnetwork machine learning model with inputs of a 3D grid 1802 ofGaussian-like atom type densities, the weights are iteratively modifiedin order to minimize the losses 1804, which is some measure of thegoodness of fit of the model outputs to the training data. In anembodiment, the procedure is performed using some variation of gradientdescent, where the changes applied to each weight during the update stepare proportional in some way to the gradient of the loss with respect tothe weight in question. The calculation of these gradients is oftenreferred to as backpropagation, as the gradients of the loss withrespect to a weight (n+1) layers removed from the model output depend,as per the chain rule, only on the gradients of the weights in thelayers (0, . . . , n) 1808 away from the model output 1805, 1806, andthey are therefore calculated first in the layer closest to the modeloutput and loss, the results of which are used both to update theweights and to calculate the gradients of the loss 1804 with respect toweights further back in the model.

Layers 1808 may perform a function with some parameters and some inputs,as long as the computation performed by a layer 1807/1803 has ananalytic derivative of the output with respect to the layer parameters(the faster to compute, the better) These parameters may then be learnedwith backpropagation. The significance of using voxelated atom-featuresas inputs to a bioactivity model (as in the case of a 3D CNN) is thatthe loss can be differentiated not only with respect to the layerweights, but also with respect to the input atom features.

According to one aspect, various cheminformatics libraries may be usedas a learned force-field for docking simulations, which perform gradientdescent of the ligand atomic coordinates with respect to the bindingaffinity 1806 and pose score 1805 (the model outputs). This requires thetask of optimizing the model loss with respect to the input features,subject to the constraints imposed upon the molecule by physics (i.e.,the conventional intramolecular forces caused for example by bondstretches still apply and constrain the molecule to remain the samemolecule). Attempting to minimize the loss 1804 directly with respect tothe input features without such constraints may end up with atomdensities that do not correspond to realistic molecules. To avoid this,one embodiment uses an autoencoder that encodes/decodes from/to theinput representation of the bioactivity model, as the compression ofchemical structures to a smaller latent space, which produces only validmolecules for any reasonable point in the latent space. Therefore, theoptimization is performed with respect to the values of the latentvector, then the optima reached corresponds to real molecules.

Application of this comprises replacing the input of a trainedbioactivity model with a decoder 1801 portion of a trained 3D CNNautoencoder, which effectively ‘lengthens’ the network by however manylayers 1808 are contained within this decoder. In the case of a 3D CNNbioactivity model, the 3D CNN autoencoder would thus form the input ofthe combined trained models. This embodiment allows both differentiablerepresentations which also have an easily decodable many-to-one mappingto real molecules since the latent space encodes the 3D structure of aparticular rotation and translation of a particular conformation of acertain molecule, therefore many latent points can decode to the samemolecule but with different arrangements in space. The derivative of theloss with respect to the atom density in a voxel allows forbackpropagation of the gradients all the way through to the latentspace, where optimization may be performed on the model output(s) 1805,1806 with respect to, not the weights, but the latent vector values.

Following this optimization, the obtained minima can be decoded backinto a real molecule by taking the decoder output and transforming theatom-densities into the best-matching molecular structure. Duringoptimization of the latent space, it is likely that some constraintsmust be applied to the latent space to avoid ending up in areas thatdecode to nonsensical atom densities.

FIG. 20 is a block diagram of an overall model architecture of a systemfor de novo drug discovery according to one embodiment. The exemplarymodel described herein is a variational autoencoder (VAE) 2001-2007together with a reinforcement learning (RL) component 2008-2010 for agraph-based approach. The aim of said model is to learn a latentdistribution that governs molecular properties and provide a decoder2004, 2009 which can construct chemically valid molecules from samplesof the prior. With reinforcement learning 2008-2010 to provide anadditional gradient signal, decoded molecules may be checked forchemical validity. Samples from the prior distribution as well asposterior distribution are decoded, and their validity is evaluated. Asmost cheminformatics toolkits chemical validity checking process is notdifferentiable, a reward prediction network (a separate MPNN encoder2011) must be used which is trained to predict the validity of inputgraph 2001. Together, these components provide an end to end, fullydifferentiable framework for training.

FIG. 21 is a block diagram of a model architecture of a MPNN encoder2002 for de novo drug discovery according to one embodiment. MPNNEncoder 2002 consists of given node 2101 and edge features 2106 that areinput to dense layers 2102, reshaped 2103, summed 2104, concatenated2105, and circulated within a message passing neural network 2107-2110,which learns a hidden representation of a molecule (Readout vector2111). This is done by continuously aggregating neighboring node 2101and edge 2106 information through a process called message passing 2107.Readout vector is subsequently split in to the mean and variance vectors2112, 2113 which serve and as the parameters of the posteriordistribution from which the latent samples 2302 are sampled.

FIG. 22 is a block diagram of a model architecture of a Sampling module2003/2008 for de novo drug discovery according to one embodiment. Thesampling module comprises a split readout function 2201 that producesthe mean and log(sigma²) of the batch. A reparameterization function2202 is used to get a differentiable sampling procedure and a sample ofN (mean, std) using a known property of the Gaussian distribution. N(mean, std) is equal to N (0, 1) times sigma plus the mean.

FIG. 23 is a block diagram of a model architecture of a decoder2004/2009 for de novo drug discovery according to one embodiment. Adecoder 2004/2009 with parameters 2301 for the maximum number of atomsto generate along with node and edge size is used to formulate thereconstruction loss 2006. Latent samples 2302 are passed through asequence of dense layers 2303 a-n and subsequently processed via twodifferent matrices to reconstruct node feature 2304 and edge feature2305 matrices. Shape functions 2306, 2307 ensure the shapes of (NoAtoms, No Node Features) and (No Atoms, No Atoms, No Edge Features)respectively. Currently this is enforced by using a maximum number ofallowed atoms to reconstruct. Further, an additional entry for each ofthe encoded feature distributions is performed, which represents thepossibility of No Atom/No Feature 2308-2310. Finally, the node and edgefeature matrices are compared using an approximate graph matchingprocedure 2006 which looks at atom types, bond types, atom-bond-atomtypes.

FIG. 24 is a block diagram of a model architecture for reinforcementlearning 2400 for de novo drug discovery according to one embodiment.The reinforcement learning 2400 as also shown in FIG. 20, comprisessamples 2003/2008 and nodes and edges that inform a reward predictionnetwork 2011. The reward prediction network 2011 receives a batch oflatent examples from the decoders 2004/2009, nodes and edges from theVAE output 2403 and the input 2001, where the output of the VAE 2403 ismade up of reconstructions of received nodes and edges from the input2001. The MPNN encoder 2011 is trained to predict rewards 2011 a-f giventhe nodes and edges. Cross entropy loss 2011 g is the sum of each of theindividual reward combinations 2011 a-f and is backpropagated throughthe reward prediction network 2011, while the VAE RL loss 2010 is fedback into the VAE output 2403.

FIG. 25 is a block diagram of a model architecture of an autoregressivedecoder 2500 for de novo drug discovery according to one embodiment.Latent vectors of size dimension z are inputs 2501 to the autoregressiondecoder 2500 and subsequently calculated into dense layers 2502 wheretheir dimensions may be expanded. A concatenation function 2503 precedesa second dense layer 2504 where pre-LSTM feature extraction occurs.After the LSTM cell function 2505, which corresponds to the LSTMrecurrence operation, another concatenation occurs 2506 before a thirddense layer 2507 extracts nonlinear features. The loop between the thirddense layer 2507 and the first concatenation has no atoms. The fourthdense layer 2508 processes atom node features for the stack 2409 tobegin node reconstruction. For each bond type a vector for the edge typeis created 2410 where the product 2411 outputs probable bond typesbetween nodes. Lastly, adjacency reconstruction 2412 is modeled by a setof edge-specific factors, (e.g., logistic sigmoid function, thecorresponding diagonal vector matrix) which are learned parameters.

FIG. 26 is a block diagram of an exemplary system architecture for a 3DBioactivity platform. According to one embodiment, a 3D bioactivitymodule 2610, comprising a docking simulator 2611 and a 3D-CNN 2612 maybe incorporated into the system described in FIG. 1 containing elements110-151. A data platform 110 scrapes empirical lab results in the formof protein-ligand pairs with a ground-truth state 2613 from publicdatabases that is then used in a docking simulator 2611 to produce adata set for which to train a three-dimensional convolutional neuralnetwork (3D-CNN 2612) classifier, which as disclosed herein is a modelthat can classify a given input of a certain protein-ligand pair isactive or inactive and whether or not the pose is correct 2614. A keyfeature of the 3D-CNN bioactivity module 2610 as disclosed herein, isthe ability to produce visualizations of the interactions in the inputthat are vital to the active/inactive classifications in a moreinterpretable manner than a FASTA-based model currently used in the art.The output incorporates gradients relating to the binding affinity ofspecific atoms that a user may use to understand where the model wasmost attentive and would further provide an explanation why specificmolecules are bioactive and why certain molecules are not and toidentify the important residues of the binding site. Once the residuesare identified, sequence-based similarities algorithms may identifysimilar motifs in other proteins from the same family or in completelynovel proteins relating to that ligand interaction. Furthermore, the3D-CNN model disclosed herein improves upon current art by penalizingthe model for incorrect docking, thus leading to a three classclassification 2614: active, inactive, and incorrect docking.

FIG. 28 is a flow diagram illustrating an exemplary method forclassifying protein-ligand pairs using a 3D Bioactivity platform. Datais generated 2810 from lab-based empirical evidence which constitutesprotein-ligand pairs and their ground-truth state. That data is sent toa docking simulation whereby energy states of the input poses are outputalong with a classification of active/inactive—from the lab data 2820.The training data presents a choice of a threshold bracket 2830. Thethreshold bracket is a trade-off between the average informationcontained in each datapoint, and the sheer quantity of data, assumingthat datapoints with more extreme inactive/active IC₅₀ values are indeedmore typical of the kind of interactions that determine whether or not aprotein-ligand pair is active or inactive. In the case of the 3D-model,using the dataset with no threshold performs consistently better acrossmost metrics. The channels used for the data set are hydrophobic,hydrogen-bond donor or acceptor, aromatic, positive or negativeionizable, metallic and total excluded volume. Regardless of the choiceof threshold, the data is then used to train a 3D-CNN to know theclassification of a molecule regarding activation and pose propriety2840. The 3D bioactivity platform then receives an unknown molecule 2850that is fed into the model to determine its classifications 2860/2870.The prediction is output 2880, and in some embodiments, may be used inbackpropagation to further inform the model.

FIG. 30 is a block diagram of an exemplary system architecture for aPoint-Cloud Bioactivity platform. Instead of representing protein-ligandcomplexes as voxel grids containing atom densities as in otherembodiments disclosed herein, this embodiment represents protein-ligandcomplexes as atoms with associated coordinates, i.e., point-cloudmodels. Point cloud models allow for pointwise operations on thesecoordinates (and in some cases operations that capture spatialrelationships between points), and, depending on the task, agglomeratethese into either a single representation that can be used for aclassification or regression task, or to perform a pointwise regressionor classification task on the set of points. An exemplary pseudocodeimplementation 3400 is presented in FIG. 34.

According to one embodiment, a point-cloud bioactivity module 3010,comprising a docking simulator 3012 and one or more transformerconvolution algorithms 3010 may be incorporated into the systemdescribed in FIG. 1 or in FIG. 26, both containing elements 110-151. Thepoint-based bioactivity module 3010 comprises two main operating stateswith two more substates in each main operating state. The first mainoperating state is a training state from which a model for the secondmain operating state is produced. The second main operating state is aplatform for which users may query one or more protein-ligand pairs andreceive a bioactivity prediction, the prediction generated from thetrained model achieved from the first main operating state. For bothmain operating states, there are two modes of operation: Coupled anddecoupled. Whether training or querying, the point-based bioactivitymodule 3010 may use the docking simulator 3012 or not. In a specificcoupled case, the docking simulator 3012 may be used initially but ifthe results are incongruent, the simulation failed, or the results areotherwise undesirable, the point-based bioactivity module 3010 willdefault to a decoupled operating state. The input 3013 to thepoint-based bioactivity module 3010, whether training or querying, aremolecular structure files. These molecular structure files are either inthe form of empirical lab results retrieved and scraped via the dataplatform 110 for the training mode of operation, or submitted by a userfor the querying mode of operation. The user may submit a protein file,or a protein file with an alternative ligand file, or coordinates of thebinding pocket, or other alternative protein-ligand file configurations.The option to use a decoupled or coupled state—whether theprotein-ligand pose propriety is known or predicted—may be decideddepending on the task at hand. Given specific time or computingconstraints, the user may manually, or the point-based bioactivitymodule 3010 may automatically choose a decoupled operating state,bypassing the docking simulator to save time or computing resources.

During the training operating state, predictions 3014 from thetransformer convolution module(s) 3011 comprise whether theprotein-ligand pair generated matches closely enough the crystalstructure of the ground-truth pair, and the bioactivity. Typically, butnot limited to, a threshold of 2 angstroms is used to determine thecrystalline structure similarity. The crystal structure similarity mayalso be used to decide whether to penalize the model for predicting toohigh a bioactivity if the crystal-structure comparison does not meet the2-angstrom threshold.

During the querying operating mode, a bioactivity prediction is output,combined from the regression output and the classification ofactive/inactive-ness. Further, a 3D dimensional model of importances isgenerated as well. The output predictions 3014, described above aremerely exemplary, and it is to be understood that in either training orquerying mode, all five outputs (active, inactive, crystal-like, notcrystal-like, and regression) or any combination thereof may be used.

Further, according to various embodiments, model ensembling, or the useand combination of various machine learning models is anticipated. Thismeans, in addition to the transformer convolution system and methoddescribed in this embodiment, other machine learning models may beintegrated within, replaced by other models, and otherwise combined insuch a way to enhance the prediction of bioactivity.

FIG. 31 is a block diagram of an exemplary model architecture for aPoint-Cloud Bioactivity platform. The output of the model comprises oneor more predictions (e.g., active or inactive, crystal structuresimilarity, regression output, and bioactivity). The outputs are taskdependent, wherein the output may contain one or more of theclassifications, regressions, a bioactivity value, or some combinationthereof. The values of regression or bioactivity may take any formdesirable to the user; however, a few exemplary values comprise units of−log₁₀(IC₅₀), or −log₁₀(Ki), or the negative log base ten of any otherbioactivity metric, which again is merely exemplary.

As described in FIG. 30, molecular structure files are used as theinputs 3100, and come from a variety of sources. As one example, a usermay upload a structural file of a protein which comprises an ID fromwhich the bioactivity platform downloads a corresponding molecularstructure file. Then the user informs the system where in the pocket theligand lies, or may upload a file of the ligand in the binding pocket,or just supply the molecular structure of a ligand. These inputs are fedas into two independent modules 3101/3102, one for the protein 3101 anda separate one for the ligand 3102. Because a point-cloud model is agraph with no edges, edges for the protein model, i.e., the proteinmodule 3101, are generated by determining the proximity of all the atomswithin a certain distance to the ligand or binding pocket. The ligandsubmodule 3102 creates edges for the ligand model from the informationcontained in the molecular structure file comprising bonds, e.g., singlebonds, double bonds, aromatic bonds, etc. For decoupled protein-ligandpairs, i.e., protein-ligand pairs where docking simulations failed orare ligand-binding pocket conformations otherwise not available 3103,pooling (Max, weighted, etc.) 3104 is performed on the protein, creatinga collapsed vector of protein atoms. For example, only protein atomsfrom the binding site are kept for decoupled pairs, while protein atomswithin 4 angstroms of the ligand are kept for a coupled model.

The output of the protein and ligand modules 3105 also includes thecombined protein-ligand complex of coupled molecules via dockingsimulations. In other words, the input to the cross attention module3105 is a concatenated atom list of the protein and ligand, wherein theedge list contains only edges where one atom is a protein, and one atomis a ligand atom. Furthermore, the cross attention module 3105 restrictsattention between protein and ligand atoms in close proximity, ergo, themodel can only learn from the actual interactions, whereas without thisrestriction, there is no coupling between protein and ligand. The vectoroutput of the cross-attention model 3105 is pooled 3106 into a singlefeature vector that feeds into a feed-forward neural network 3107.

One set of outputs is a crystal-structure similarity analysis 3114,which is comprised from two output nodes 3109 a-b that are sent througha SoftMax function 3112, and predict whether the protein-ligand pair inquestion is similar enough to the ground truth crystal structure(typically within a 2 angstroms threshold) 3111. Typically, thecrystallization analysis 3114 is only used for training, however outputduring a user query is anticipated. Another output comprises a SoftMaxfunction 3111 containing two output nodes of the active/inactiveprediction 3108 a-b of the protein-ligand pair in question and producinga prediction 3113 of that active/inactive status. The regression output3110 and active-ness prediction 3113 inform the bioactivity predictionvalue 3115. A user query may return in addition to a bioactivityprediction 3115, a 3D visualization 3116 of the queried protein-ligandpair with various information about the importances as laid out in FIG.33.

During training of the model, a loss function 3117 is used and isconfigured to penalize the model if the model predicts too high abioactivity for a non-crystal-like structured protein-ligand pair, butis not penalized for predicting too low a bioactivity, while alsosimultaneously trained on the classification task. At prediction time,the model may use the crystal structure probability to decide whether totake bioactivity reading or discard it as inaccurate. From there moredocking poses may be generated until a likely crystal structure isfound.

Detailed Description of Exemplary Aspects

FIG. 10 is a diagram illustrating an exemplary architecture forprediction of molecule bioactivity using concatenation of outputs from agraph-based neural network which analyzes molecules and their known orsuspected bioactivities with proteins and a sequence-based neuralnetwork which analyzes protein segments and their known or suspectedbioactivities with molecules. In this architecture, in a first neuralnetwork processing stream, SMILES data 1010 for a plurality of moleculesis transformed at a molecule graph construction stage 1013 into agraph-based representation wherein each molecule is represented as agraph comprising nodes and edges, wherein each node represents an atomand each edge represents a connection between atoms of the molecule.Each node represents the atom as node features comprising an atom typeand a number of bonds available for that atom. The node features arerepresented as a node features matrix 1012. The molecule, then, isrepresented as nodes (atoms) connected by edges (bonds), and isspecified as an adjacency matrix 1011 showing which nodes (atoms) areconnected to which other nodes (atoms).

At the training stage, the adjacency matrices 1011 and node featuresmatrices 1012 for many molecules are input into the MPNN 1020 along withvector representations of known or suspected bioactivity interactions ofeach molecule with certain proteins. Based on the training data, theMPNN 1020 learns the characteristics of molecules and proteins thatallow interactions and what the bioactivity associated with thoseinteractions is. At the analysis stage, a target molecule is input intothe MPNN 1020, and the output of the MPNN 1020 is a vectorrepresentation of that molecule's likely interactions with proteins andthe likely bioactivity of those interactions.

Once the molecule graph construction 1013 is completed, the nodefeatures matrices 1012 and adjacency matrices 1011 are passed to amessage passing neural network (MPNN) 1020, wherein the processing isparallelized by distributing groups 1021 nodes of the graph amongst aplurality of processors (or threads) for processing. Each processor (orthread) performs attention assignment 1022 on each node, increasing ordecreasing the strength of its relationships with other nodes, andoutputs of the node and signals to other neighboring nodes 1023 (i.e.,nodes connected by edges) based on those attention assignments aredetermined. Messages are passed 1024 between neighboring nodes based onthe outputs and signals, and each node is updated with the informationpassed to it. Messages can be passed between processors and/or threadsas necessary to update all nodes. In some embodiments, this messagepassing (also called aggregation) process is accomplished by performingmatrix multiplication of the array of node states by the adjacencymatrix to sum the value of all neighbors or divide each column in thematrix by the sum of that column to get the mean of neighboring nodestates. This process may be repeated an arbitrary number of times. Onceprocessing by the MPNN is complete, its results are sent forconcatenation 1050 with the results from a second neural network, inthis case a long short term memory neural network 1040 which analyzesprotein structure.

In a second processing stream, FASTA data 1030 is converted tohigh-dimensional vectors 1031 representing the amino acid structure ofproteins. The vectors are processed by a long short term memory (LSTM)neural network 1040 which performs one or more iterations of attentionassignment 1041 and vector updating 1042. The attention assignment 1041of the LSTM 1040 operates in the same way as that of the MPNN 1020,although the coding implementation will be different. At the vectorupdating stage 1042, the vectors comprising each cell of the LSTM 1040are updated based on the attention assignment 1041. This process may berepeated an arbitrary number of times. Once processing by the LSTM 1040is complete, its results are sent for concatenation 1050 with theresults from the first processing stream, in this case the MPNN 1020.

Concatenation of the outputs 1050 from two different types of neuralnetworks (here an MPNN 1020 and an LSTM 1040) determines which moleculestructures and protein structures are compatible, allowing forprediction of bioactivity 1051 based on known or suspected similaritieswith other molecules and proteins.

FIGS. 11A and 11B illustrate an exemplary implementation of thearchitecture for prediction of molecule bioactivity using concatenationof outputs from a graph-based neural network which analyzes moleculestructure and a sequence-based neural network which analyzes proteinstructure. In this example, details regarding a particularimplementation of the general architecture shown in FIG. 10 aredescribed.

As shown in FIG. 11A, node features 1111 are received for processing. Areshaping process 1112 may be performed which to conform thedimensionality of the inputs to the dimensionality required forprocessing by the MPNN. A dense function 1113 is performed to map eachnode in the previous layer of the neural network to every node in thenext layer. Attention is then assigned 1114 using the adjacency matrixcontained in the node. The adjacency features (the adjacency matrix)1115 are simultaneously reshaped 1116 to conform the dimensionality ofthe inputs to the dimensionality required for processing by the MPNN.

At this stage, a message passing operation 1120 is performed, comprisingthe steps of performing a dense function 1121 (used only on the firstmessage pass) to map each node in the previous layer of the neuralnetwork to every node in the next layer, matrix multiplication of theadjacencies 1122, reshaping of the new adjacencies 1123, and where themessage passing operation has been parallelized among multipleprocessors or threads, concatenating the outputs of the variousprocessors or threads 1124.

Subsequently, a readout operation 1130 is performed comprisingperformance of a dense function 1131 and implementation of an activationfunction 1132 such as tan h, selu, etc. to normalize the outputs to acertain range. In this embodiment, the readout operation 1130 isperformed only at the first message pass of the MPNN 1110.

As shown in FIG. 11B, FASTA data is converted to high-dimensionalvectors 1151, which may then be masked 1152 to conform the vectors tothe fixed input length required by the LSTM 1153. The LSTM 1153 thenprocesses the vectors using an attention mechanism 1160 comprising thesteps of performing a dense function 1161 to map each node in theprevious layer of the neural network to every node in the next layer,performing a softmax function 1162 to assign probabilities to each nodejust before the output layer. The process is repeated a number of timeswhich may be configured by a parameter 1163. Where permutationinvariance is an issue (i.e., where changes in the order of inputs yieldchanges in the outputs), permutations may be applied to the inputs 1164to ensure that differences in outputs due to differences in inputs areincorporated.

After attention has been assigned 1160, the vectors in the cells of theLSTM 1153 are multiplied 1154, summed 1155, and a dense function 1156 isagain applied to map each node in the previous layer of the neuralnetwork to every node in the next layer, and the outputs of the LSTM1153 are sent for concatenation 1141 with the outputs of the MPNN 1110,after which predictions can be made 1142.

FIG. 12 illustrates an exemplary implementation of an attentionassignment aspect of an architecture for prediction of moleculebioactivity using concatenation of outputs from a graph-based neuralnetwork which analyzes molecule structure and a sequence-based neuralnetwork which analyzes protein structure. This is an exemplaryimplementation of attention and may not be representative of a preferredembodiment. In this example, details regarding a particularimplementation of the attention assignment blocks shown in FIG. 10 aredescribed. The particular implementation of this example involves amulti-head attention mechanism.

As node features 1201 are received for processing, they are updated 1202and sent for later multiplication 1203 with the outputs of the multipleattention heads 1207. Simultaneously, the nodes are masked 1204 toconform their lengths to a fixed input length required by the attentionheads 1207. The adjacency matrix 1205 associated with (or contained in)in each node is also masked 1206 to conform it to a fixed length andsent along with the node features to the multi-head attention mechanism1207.

The multi-head attention mechanism 1207 comprises the steps of assigningattention coefficients 1208, concatenating all atoms to all other atoms1209 (as represented in the adjacency matrix), combining thecoefficients 1210, performing a Leaky ReLU 1211 function to assignprobabilities to each node just before the output layer, and performingmatrix multiplication 1212 on the resulting matrices.

The outputs of the multi-head attention mechanism 1207 are thenconcatenated 1214, and optionally sent to a drawing program for displayof the outputs in graphical form 1213. A sigmoid function 1215 isperformed on the concatenated outputs 1214 to normalize the outputs to acertain range. The updated node features 1202 are then multiplied 1203with the outputs of the multi-head attention mechanism 1207, and sentback to the MPNN.

FIG. 13 is a diagram illustrating an exemplary architecture forprediction of molecule bioactivity using concatenation of outputs from agraph-based neural network which analyzes molecules and their known orsuspected bioactivities with proteins and a sequence-based neuralnetwork which analyzes protein segments and their known or suspectedbioactivities with molecules. In this architecture, in a first neuralnetwork processing stream, SMILES data 1310 for a plurality of moleculesis transformed at a molecule graph construction stage 1313 into agraph-based representation wherein each molecule is represented as agraph comprising nodes and edges, wherein each node represents an atomand each edge represents a connection between atoms of the molecule.Each node represents the atom as node features comprising an atom typeand a number of bonds available for that atom. The node features arerepresented as a node features matrix 1312. The molecule, then, isrepresented as nodes (atoms) connected by edges (bonds), and isspecified as an adjacency matrix 1311 showing which nodes (atoms) areconnected to which other nodes (atoms).

At the training stage, the adjacency matrices 1311 and node featuresmatrices 1312 for many molecules are input into the MPNN 1320 along withvector representations of known or suspected bioactivity interactions ofeach molecule with certain proteins. Based on the training data, theMPNN 1320 learns the characteristics of molecules and proteins thatallow interactions and what the bioactivity associated with thoseinteractions is. At the analysis stage, a target molecule is input intothe MPNN 1320, and the output of the MPNN 1320 is a vectorrepresentation of that molecule's likely interactions with proteins andthe likely bioactivity of those interactions.

Once the molecule graph construction 1013 is completed, the nodefeatures matrices 1012 and adjacency matrices 1011 are passed to amessage passing neural network (MPNN) 1020, wherein the processing isparallelized by distributing groups 1321 nodes of the graph amongst aplurality of processors (or threads) for processing. Each processor (orthread) performs attention assignment 1322 on each node, increasing ordecreasing the strength of its relationships with other nodes, andoutputs of the node and signals to other neighboring nodes 1323 (i.e.,nodes connected by edges) based on those attention assignments aredetermined. Messages are passed between neighboring nodes based on theoutputs and signals, and each node is updated with the informationpassed to it. Messages can be passed between 1324 processors and/orthreads as necessary to update all nodes. In some embodiments, thismessage passing (also called aggregation) process is accomplished byperforming matrix multiplication of the array of node states by theadjacency matrix to sum the value of all neighbors or divide each columnin the matrix by the sum of that column to get the mean of neighboringnode states. This process may be repeated an arbitrary number of times.Once processing by the MPNN is complete, its results are sent forconcatenation 1350 with the results from a second machine learningalgorithm, in this case an encoding-only transformer 1340.

In a second processing stream, FASTA data 1330 is converted tohigh-dimensional vectors 1331 representing the chemical structure ofmolecules. The vectors are processed by an encoding-only transformer1340 which performs one or more iterations of multi-head attentionassignment 1341 and concatenation 1342. Once processing by theencoding-only transformer 1340 is complete, its results are sent forconcatenation 1350 with the results from the neural network, in thiscase the MPNN 1320.

Concatenation of the outputs 1350 from two different types of neuralnetworks (here an MPNN 1320 and an LSTM 1340) determines which moleculestructures and protein structures are compatible, allowing forprediction of bioactivity 1351 based the information learned by theneural networks from the training data.

FIG. 19 is a diagram illustrating molecule encodings in latent space1901. Once a model is trained that achieves a desirable reconstructionaccuracy, a pipeline uses the model to generate molecules similar to atarget dataset. Evaluating the generated molecules for chemical validityis performed using defined metrics to compare the generated data and togauge whether the generation method is performing well. There are a fewways to compare how well the generation process works. When attemptingto reconstruct the same molecule, the models sometimes produce moleculesthat are chemically impossible. It is therefore informative to comparethe validity ratio of the generated molecules to the validity ratio ofthe reconstructed molecules of the active dataset. Ideally, the ratio issimilar. If, on the other hand, the validity of the generated data islower, it might mean that: (a) the exploration method of the latentspace is not suitable—the explored space goes beyond the chemicallymeaningful regions; (b) the latent space representation is not smoothenough. A second method is by using molecular weight. The generatedmolecules are expected to have a similar molecular weight distributionto the active samples—a discrepancy would signal problems similar tothose above. Lastly, chemical similarity. Computing and comparing thechemical similarity coefficients to estimate the molecular similarity ofthe generated and active molecules. This similarity should match thesimilarity of the active compounds amongst one another. These metricscan be used as a simple check validity (i.e., to see if the generatedmolecules “make sense”). Validity checking is particularly important incases where certain properties are imposed, such as log P or molecularweight, to the generated molecules, as this is done by modifying theelements in the latent space, and allow the system to find the viableranges of these parameters by finding where the above metrics start todeteriorate.

New molecules are generated by estimating a distribution of latent space1902 that the active molecules are embedded into, then sampling fromthis distribution 1902 and running the samples through a decoder torecover new molecules. The distribution is approximated by amultivariate Gaussian, with mean and covariance matrices computed fromthe latent representations of the active molecules.

FIG. 27 is a block diagram of an exemplary model architecture for a 3DBioactivity platform 2700. The model architecture used is athree-dimensional convolutional neural network (3D-CNN) 2730.Convolutional Neural Networks 2730 are widely used on tasks such asimage classification. They are multi-layer perceptrons that areregularized in such a way as to take advantage of the translationalinvariance of the content of pictures (e.g., a gavel is a gavel whetherit is in the center or corner of an image.). In a convolutional layer,each output neuron is not connected to all the input neurons, but to aspatially-localized subset. CNN architectures operate analogously inhigher-dimensional spaces. Docking simulations 2720/2750 take as inputthe ligand and protein molecules 2710/2740 and their three-dimensionalstructures. Docking 2720 assigns scores to each pose 2721/2722 to beused in the model 2731 depending on the embodiment. Some embodiments mayuse all poses, whereas other embodiments use only the highest scoredpose for active molecules and all poses for inactive molecules. Afterdocking simulations 2720/2750 have been completed, molecules arevoxelated and are used as the model 2731 input, which are used to trainthe model 2731 to predict 2760 or classify these voxelatedrepresentations into active/inactive and pose propriety categories.

In reality, the observed bioactivity of a ligand is not due to a singlepose within the binding site, but due to the contributions from a numberof possible poses. According to one embodiment, the population of agiven pose is given as:

$W_{b} = e^{\frac{- E}{kT}}$where E, k and T correspond to the free energy of binding, Boltzmann'sconstant, and the temperature, respectively. An estimate of E from theForce Field can be determined, and subsequently the loss may be definedas:

$L = \frac{\sum\limits_{poses}\left( {W_{b}*\left( {{{Model}({pose})} - {True\_ affinity}} \right)^{2}} \right)}{\sum\limits_{poses}\left( W_{b} \right)}$This loss function corresponds to interpreting E not as the true freeenergy of binding, but instead as the probability of a pose being the“true” pose. This method allows for superimposing theprobability-weighted atom density grids, which speeds computation upenormously. The loss function above is merely exemplary andmodifications to the loss function above are anticipated.

According to an aspect of various embodiments, an additional ‘PoseScore’ output node to the CNN is improvised. 3D-CNNs 2730 comprise anadditional output node that is trained on classifying the input poses asbeing “low” root-mean-square deviation (RMSD) (<2 Angstrom RMSD vs.crystal structure) and “high” RMSD (>2 Angstrom RMSD vs. crystalstructure). This predicted classification is used to modulate thebinding-affinity loss as follows: Affinity prediction is trained usingan L2-like pseudo-Huber loss that is hinged when evaluating high RMSDposes. That is, the model is penalized for predicting both a too low andtoo high affinity of a low RMSD pose, but only penalized for predictingtoo high an affinity for a high RMSD pose. Since the PDB dataset usedcomprises crystal structures for each available datapoint, it ispossible to generate corresponding classification labels into high/lowRSMD poses for each docked complex. Two aspects of various embodimentsare therefore anticipated. The first aspect comprises extracting RMSDlabels for datapoints where crystal structures are available and do notcontribute any “Pose Score” loss to the remaining items. The secondaspect comprises using Boltzmann-averaging of pose predictions. Thissecond aspect has the advantage of not requiring crystal structures ofany complexes.

The output 2770 of the model 2731 may combine the separate poses attest-time. Actions taken on the predictions may be selected from one ofthe actions in the list comprising: Analogous Boltzmann-weighing of thepredictions, Averaging of the predictions across all poses, simplepredictions only on the best pose, or any combination thereof.

The visualizations 2770 produced by the model 2731 may use methods suchas integrated gradients, which require only a single forwards/backwardspass of the models, which is an improvement over the current state ofthe art. According to various embodiments, integrated gradients, andother gradient visualizations are achieved by computing the voxelsaliencies, and coloring a surface/molecule of its properties. If aMaxPool layer is an initial layer of the model 2731, simple smoothing(i.e., halving the resolution of the grid) may correct the visualizationfrom the zero-average voxel-importance.

Other visualizations methods comprise assigning voxel-gradients back tothe atoms of the input molecules, which are adapted to propagatewhatever importances are computed for each voxel. Importances providethe user with an explanation of which parts of the protein-ligand pairthe model 2731 predicts is most strongly bonded. The more important theatom, the higher the number. The number may be represented by one ormore colors or shading. The importance reference system described above,i.e., the color-coordinated importances, is only one example of animportance reference system. Other methods such as coloring, shading,numbering, lettering, and the like may be used.

One use of the exemplary 3D bioactivity platform 2700 embodimentdisclosed herein comprises a user 2780 that inputs unknown moleculeconformations 2740 into the 3D bioactivity platform 2700 and receivesback a prediction as to whether the molecule is active or inactive, apose score (telling the propriety of the pose), and a 3D model completewith gradient representations of the significant residues 2760/2770.

FIG. 29 is a flow diagram illustrating an exemplary method forgenerating data for use in training a 3D-CNN used by a 3D Bioactivityplatform. Training data is generated for the training of the classifiervia docking, wherein the method of docking gives the energy states ofeach protein-ligand pose. The lower the energy state, the stronger thebinding affinity. Inputs for the docking mechanism comprise a particularprotein-ligand pair and its ground-truth state (i.e., whether it isactive or inactive) 2910. On such a pair, the docking simulation isperformed and if the pair is labeled as inactive, all data points arekept in the training dataset, if an active label is found as the groundtruth state, only the best (lowest energy) pose is kept. According toanother embodiment, the top 20 (lowest energy) poses are kept for thetraining dataset. Further anticipated embodiments acknowledge that anynumber of poses may be kept for training and the examples containedherein are merely exemplary. According to aspects of variousembodiments, simple force-field based optimization of a ligand pose in abinding pocket can substitute for docked poses at reduced computationalexpense in a binding affinity prediction task without a significantdecrease in accuracy. Force-field optimization considers at least one ofthe constant terms selected from the list of dissociation, inhibition,and half-concentration (IC50) in order to capture the molecularinteractions, e.g., hydrogen bonds, hydrophobic bonds, etc. Manydatabases known in the art may be used to get this information such asthe Protein Data Bank (PDB) as one example. In simple terms, dockingguides the machine learning (3D-CNN) to realize what poses to keep andto realize what the molecule likely looks like in the pocket.

Prior to featurization, the model input should be a cubic grid centeredaround the binding site of the complex, the data being the location andatom type of each atom in each the protein and ligand, flagged as tobelonging either to the protein or the ligand. This is trivial forcomplexes with known structures, wherein the binding site is the centerof the ligand. For unseen data, two exemplary options are anticipated:generate complexes using docking, or generate complexes by samplingligand poses.

According to one embodiment, an initial step in dataset creation is toextract the binding sites from all the proteins for which have knownstructures (this need only be done once ever) 2920. Next, using theaforementioned docking option, complexes are created via dockingsimulations 2930. However, if the foregoing second option is used, thensampling the ligands in the binding site using the cropped proteinstructures may be done post-step three for faster data loading 2950. Thenext step 2940 is to crop to a 24 Angstrom box around the binding-sitecenter (either geometric or center-of-mass). The data is then voxelated2960 and stored in a dataset 2970. Different box sizes or centeringchoices is anticipated, however, in one embodiment, the data isvoxelated to a certain resolution, e.g., 0.5 Angstrom. This resolutionis sensible as it ensures no two atoms occupy the same voxel.

FIG. 32 is a flow diagram illustrating an exemplary method forclassifying protein-ligand pairs using a Point-Cloud Bioactivityplatform. A first pass through the method illustrated described is totrain the model for future queries of user submitted protein-ligandpairs. In such a case, ground-truth protein-ligand pairs (in the form ofmolecular structure files) 3201 are used in docking simulations 3202 todetermine one or more best poses of the molecular conformation. Dockingsimulations guide the machine learning to realize what poses to keep andto realize what the molecule likely looks like in the pocket. Next,docking simulations output molecular structure files that are used bytransformer convolution classifiers to generate edges between the atomiccoordinates of the proteins and ligands 3203. If the docking simulationsfail, protein atoms of interest are pooled into a single vector 3204 andconcatenated with the ligand feature vector 3205, otherwise the proteinatoms within a spatial threshold of some amount (according to oneembodiment, 4 angstroms) are kept and concatenated with the ligandvector 3205. An attention-restricted (also cross-attention) transformerconvolution classifier is used to learn the importances and interactionsbetween the protein-ligand pair 3206. The cross-attention module outputsa feature vector for each atom in each molecule which is then pooledinto a single feature vector for each molecule 3207. A neural network—afeed-forward neural network in a preferred embodiment—outputs one tofive outputs 3208 depending on the task, which in turn may make up tothree predictions. One output is a prediction of the generatedprotein-ligand pair's active or inactive nature, while another iswhether the crystal structure closely matches the crystal structure ofthe ground-truth pair, typically within 2 angstroms 3209. The regressionis used to determine bioactivity which may be a numerical valuegenerated by a regression task and based off one or more bioactivitymetrics such as the pair's inhibition constant, IC₅₀, or another metric.During training, outputs are fed into a loss function and optimizer forbackpropagation as is typical of machine learning 3210, while also usingthe crystalline structure similarity prediction to determine thelegitimacy of the model's bioactivity prediction.

A second pass through the diagram illustrates the case of employing analready trained point-cloud based bioactivity prediction model asdescribed above. A user may submit a query, in the form of a molecularstructure file, or other format which is then turned into a molecularstructure file, and receive in return one or more predictions selectedfrom the list of active classification, crystal similarityclassification, regression task, combined active/crystal classification,a bioactivity classification, or some combination thereof, as well as athree-dimensional point-cloud based visualization 3211 highlightingimportances and saliences of the queried molecule. Further informationon the visualization follows in the next figure.

FIG. 33 is a block diagram illustrating an exemplary point-basedvisualization. This diagram is merely for illustrative purposes and isnot to scale, may not reflect actual protein-ligand interactions, andmay not accurately reflect the visualizations produced by thepoint-cloud bioactivity module. In this diagram of a point-basedvisualization, a protein 3301 and ligand molecule 3302 show directly theimportance assigned to protein-ligand interactions represented by size3308, shading 3303/3304, and dashed lines 3305. The point-basedvisualization colors atoms 3303/3304 according to thepositive/negative-ness of the saliencies obtained through integratedgradients, values of attention coefficients, or any variation thereof,as well as scaling their size 3308 according to the magnitude, as can beseen by the larger atoms. Colored dashed lines 3305-3307 are used tohighlight importance attributed to interactions and are typically, butnot limited to be always within 4 angstroms of each other.

This visualization is based on a point-cloud model with a transformerconvolution architecture. This allows specification of edge features anddoes not require padding, and is thus the preferred point-based modelarchitecture according to one embodiment. This embodiment performsgraph-message-passes with messages computed using attention ofneighbors, whilst taking edge features into account. By computing theimportance with respect to the protein-ligand edge features (which areembeddings of the distance into a series of sinusoids of variousfrequencies, analogous to the positional embedding used in transformermodels), and considering all protein-ligand atom-pairs within 4 Angstromof one another to be connected by edges, model attributions to certaininteractions may be directly highlighted.

Hardware Architecture

Generally, the techniques disclosed herein may be implemented onhardware or a combination of software and hardware. For example, theymay be implemented in an operating system kernel, in a separate userprocess, in a library package bound into network applications, on aspecially constructed machine, on an application-specific integratedcircuit (ASIC), or on a network interface card.

Software/hardware hybrid implementations of at least some of the aspectsdisclosed herein may be implemented on a programmable network-residentmachine (which should be understood to include intermittently connectednetwork-aware machines) selectively activated or reconfigured by acomputer program stored in memory. Such network devices may havemultiple network interfaces that may be configured or designed toutilize different types of network communication protocols. A generalarchitecture for some of these machines may be described herein in orderto illustrate one or more exemplary means by which a given unit offunctionality may be implemented. According to specific aspects, atleast some of the features or functionalities of the various aspectsdisclosed herein may be implemented on one or more general-purposecomputers associated with one or more networks, such as for example anend-user computer system, a client computer, a network server or otherserver system, a mobile computing device (e.g., tablet computing device,mobile phone, smartphone, laptop, or other appropriate computingdevice), a consumer electronic device, a music player, or any othersuitable electronic device, router, switch, or other suitable device, orany combination thereof. In at least some aspects, at least some of thefeatures or functionalities of the various aspects disclosed herein maybe implemented in one or more virtualized computing environments (e.g.,network computing clouds, virtual machines hosted on one or morephysical computing machines, or other appropriate virtual environments).

Referring now to FIG. 35, there is shown a block diagram depicting anexemplary computing device 10 suitable for implementing at least aportion of the features or functionalities disclosed herein. Computingdevice 10 may be, for example, any one of the computing machines listedin the previous paragraph, or indeed any other electronic device capableof executing software- or hardware-based instructions according to oneor more programs stored in memory. Computing device 10 may be configuredto communicate with a plurality of other computing devices, such asclients or servers, over communications networks such as a wide areanetwork a metropolitan area network, a local area network, a wirelessnetwork, the Internet, or any other network, using known protocols forsuch communication, whether wireless or wired.

In one aspect, computing device 10 includes one or more centralprocessing units (CPU) 12, one or more interfaces 15, and one or morebusses 14 (such as a peripheral component interconnect (PCI) bus). Whenacting under the control of appropriate software or firmware, CPU 12 maybe responsible for implementing specific functions associated with thefunctions of a specifically configured computing device or machine. Forexample, in at least one aspect, a computing device 10 may be configuredor designed to function as a server system utilizing CPU 12, localmemory 11 and/or remote memory 16, and interface(s) 15. In at least oneaspect, CPU 12 may be caused to perform one or more of the differenttypes of functions and/or operations under the control of softwaremodules or components, which for example, may include an operatingsystem and any appropriate applications software, drivers, and the like.

CPU 12 may include one or more processors 13 such as, for example, aprocessor from one of the Intel, ARM, Qualcomm, and AMD families ofmicroprocessors. In some aspects, processors 13 may include speciallydesigned hardware such as application-specific integrated circuits(ASICs), electrically erasable programmable read-only memories(EEPROMs), field-programmable gate arrays (FPGAs), and so forth, forcontrolling operations of computing device 10. In a particular aspect, alocal memory 11 (such as non-volatile random access memory (RAM) and/orread-only memory (ROM), including for example one or more levels ofcached memory) may also form part of CPU 12. However, there are manydifferent ways in which memory may be coupled to system 10. Memory 11may be used for a variety of purposes such as, for example, cachingand/or storing data, programming instructions, and the like. It shouldbe further appreciated that CPU 12 may be one of a variety ofsystem-on-a-chip (SOC) type hardware that may include additionalhardware such as memory or graphics processing chips, such as a QUALCOMMSNAPDRAGON™ or SAMSUNG EXYNOS™ CPU as are becoming increasingly commonin the art, such as for use in mobile devices or integrated devices.

As used herein, the term “processor” is not limited merely to thoseintegrated circuits referred to in the art as a processor, a mobileprocessor, or a microprocessor, but broadly refers to a microcontroller,a microcomputer, a programmable logic controller, anapplication-specific integrated circuit, and any other programmablecircuit.

In one aspect, interfaces 15 are provided as network interface cards(NICs). Generally, NICs control the sending and receiving of datapackets over a computer network; other types of interfaces 15 may forexample support other peripherals used with computing device 10. Amongthe interfaces that may be provided are Ethernet interfaces, frame relayinterfaces, cable interfaces, DSL interfaces, token ring interfaces,graphics interfaces, and the like. In addition, various types ofinterfaces may be provided such as, for example, universal serial bus(USB), Serial, Ethernet, FIREWIRE™, THUNDERBOLT™, PCI, parallel, radiofrequency (RF), BLUETOOTH™, near-field communications (e.g., usingnear-field magnetics), 802.11 (WiFi), frame relay, TCP/IP, ISDN, fastEthernet interfaces, Gigabit Ethernet interfaces, Serial ATA (SATA) orexternal SATA (ESATA) interfaces, high-definition multimedia interface(HDMI), digital visual interface (DVI), analog or digital audiointerfaces, asynchronous transfer mode (ATM) interfaces, high-speedserial interface (HSSI) interfaces, Point of Sale (POS) interfaces,fiber data distributed interfaces (FDDIs), and the like. Generally, suchinterfaces 15 may include physical ports appropriate for communicationwith appropriate media. In some cases, they may also include anindependent processor (such as a dedicated audio or video processor, asis common in the art for high-fidelity AN hardware interfaces) and, insome instances, volatile and/or non-volatile memory (e.g., RAM).

Although the system shown in FIG. 35 illustrates one specificarchitecture for a computing device 10 for implementing one or more ofthe aspects described herein, it is by no means the only devicearchitecture on which at least a portion of the features and techniquesdescribed herein may be implemented. For example, architectures havingone or any number of processors 13 may be used, and such processors 13may be present in a single device or distributed among any number ofdevices. In one aspect, a single processor 13 handles communications aswell as routing computations, while in other aspects a separatededicated communications processor may be provided. In various aspects,different types of features or functionalities may be implemented in asystem according to the aspect that includes a client device (such as atablet device or smartphone running client software) and server systems(such as a server system described in more detail below).

Regardless of network device configuration, the system of an aspect mayemploy one or more memories or memory modules (such as, for example,remote memory block 16 and local memory 11) configured to store data,program instructions for the general-purpose network operations, orother information relating to the functionality of the aspects describedherein (or any combinations of the above). Program instructions maycontrol execution of or comprise an operating system and/or one or moreapplications, for example. Memory 16 or memories 11, 16 may also beconfigured to store data structures, configuration data, encryptiondata, historical system operations information, or any other specific orgeneric non-program information described herein.

Because such information and program instructions may be employed toimplement one or more systems or methods described herein, at least somenetwork device aspects may include nontransitory machine-readablestorage media, which, for example, may be configured or designed tostore program instructions, state information, and the like forperforming various operations described herein. Examples of suchnontransitory machine-readable storage media include, but are notlimited to, magnetic media such as hard disks, floppy disks, andmagnetic tape; optical media such as CD-ROM disks; magneto-optical mediasuch as optical disks, and hardware devices that are speciallyconfigured to store and perform program instructions, such as read-onlymemory devices (ROM), flash memory (as is common in mobile devices andintegrated systems), solid state drives (SSD) and “hybrid SSD” storagedrives that may combine physical components of solid state and hard diskdrives in a single hardware device (as are becoming increasingly commonin the art with regard to personal computers), memristor memory, randomaccess memory (RAM), and the like. It should be appreciated that suchstorage means may be integral and non-removable (such as RAM hardwaremodules that may be soldered onto a motherboard or otherwise integratedinto an electronic device), or they may be removable such as swappableflash memory modules (such as “thumb drives” or other removable mediadesigned for rapidly exchanging physical storage devices),“hot-swappable” hard disk drives or solid state drives, removableoptical storage discs, or other such removable media, and that suchintegral and removable storage media may be utilized interchangeably.Examples of program instructions include both object code, such as maybe produced by a compiler, machine code, such as may be produced by anassembler or a linker, byte code, such as may be generated by forexample a JAVA™ compiler and may be executed using a Java virtualmachine or equivalent, or files containing higher level code that may beexecuted by the computer using an interpreter (for example, scriptswritten in Python, Perl, Ruby, Groovy, or any other scripting language).

In some aspects, systems may be implemented on a standalone computingsystem. Referring now to FIG. 36, there is shown a block diagramdepicting a typical exemplary architecture of one or more aspects orcomponents thereof on a standalone computing system. Computing device 20includes processors 21 that may run software that carry out one or morefunctions or applications of aspects, such as for example a clientapplication 24. Processors 21 may carry out computing instructions undercontrol of an operating system 22 such as, for example, a version ofMICROSOFT WINDOWS™ operating system, APPLE macOS™ or iOS™ operatingsystems, some variety of the Linux operating system, ANDROID™ operatingsystem, or the like. In many cases, one or more shared services 23 maybe operable in system 20, and may be useful for providing commonservices to client applications 24. Services 23 may for example beWINDOWS™ services, user-space common services in a Linux environment, orany other type of common service architecture used with operating system21. Input devices 28 may be of any type suitable for receiving userinput, including for example a keyboard, touchscreen, microphone (forexample, for voice input), mouse, touchpad, trackball, or anycombination thereof. Output devices 27 may be of any type suitable forproviding output to one or more users, whether remote or local to system20, and may include for example one or more screens for visual output,speakers, printers, or any combination thereof. Memory 25 may berandom-access memory having any structure and architecture known in theart, for use by processors 21, for example to run software. Storagedevices 26 may be any magnetic, optical, mechanical, memristor, orelectrical storage device for storage of data in digital form (such asthose described above, referring to FIG. 35). Examples of storagedevices 26 include flash memory, magnetic hard drive, CD-ROM, and/or thelike.

In some aspects, systems may be implemented on a distributed computingnetwork, such as one having any number of clients and/or servers.Referring now to FIG. 37, there is shown a block diagram depicting anexemplary architecture 30 for implementing at least a portion of asystem according to one aspect on a distributed computing network.According to the aspect, any number of clients 33 may be provided. Eachclient 33 may run software for implementing client-side portions of asystem; clients may comprise a system 20 such as that illustrated inFIG. 36. In addition, any number of servers 32 may be provided forhandling requests received from one or more clients 33. Clients 33 andservers 32 may communicate with one another via one or more electronicnetworks 31, which may be in various aspects any of the Internet, a widearea network, a mobile telephony network (such as CDMA or GSM cellularnetworks), a wireless network (such as WiFi, WiMAX, LTE, and so forth),or a local area network (or indeed any network topology known in theart; the aspect does not prefer any one network topology over anyother). Networks 31 may be implemented using any known networkprotocols, including for example wired and/or wireless protocols.

In addition, in some aspects, servers 32 may call external services 37when needed to obtain additional information, or to refer to additionaldata concerning a particular call. Communications with external services37 may take place, for example, via one or more networks 31. In variousaspects, external services 37 may comprise web-enabled services orfunctionality related to or installed on the hardware device itself. Forexample, in one aspect where client applications 24 are implemented on asmartphone or other electronic device, client applications 24 may obtaininformation stored in a server system 32 in the cloud or on an externalservice 37 deployed on one or more of a particular enterprise's oruser's premises. In addition to local storage on servers 32, remotestorage 38 may be accessible through the network(s) 31.

In some aspects, clients 33 or servers 32 (or both) may make use of oneor more specialized services or appliances that may be deployed locallyor remotely across one or more networks 31. For example, one or moredatabases 34 in either local or remote storage 38 may be used orreferred to by one or more aspects. It should be understood by onehaving ordinary skill in the art that databases in storage 34 may bearranged in a wide variety of architectures and using a wide variety ofdata access and manipulation means. For example, in various aspects oneor more databases in storage 34 may comprise a relational databasesystem using a structured query language (SQL), while others maycomprise an alternative data storage technology such as those referredto in the art as “NoSQL” (for example, HADOOP CASSANDRA™, GOOGLEBIGTABLE™, and so forth). In some aspects, variant databasearchitectures such as column-oriented databases, in-memory databases,clustered databases, distributed databases, or even flat file datarepositories may be used according to the aspect. It will be appreciatedby one having ordinary skill in the art that any combination of known orfuture database technologies may be used as appropriate, unless aspecific database technology or a specific arrangement of components isspecified for a particular aspect described herein. Moreover, it shouldbe appreciated that the term “database” as used herein may refer to aphysical database machine, a cluster of machines acting as a singledatabase system, or a logical database within an overall databasemanagement system. Unless a specific meaning is specified for a givenuse of the term “database”, it should be construed to mean any of thesesenses of the word, all of which are understood as a plain meaning ofthe term “database” by those having ordinary skill in the art.

Similarly, some aspects may make use of one or more security systems 36and configuration systems 35. Security and configuration management arecommon information technology (IT) and web functions, and some amount ofeach are generally associated with any IT or web systems. It should beunderstood by one having ordinary skill in the art that anyconfiguration or security subsystems known in the art now or in thefuture may be used in conjunction with aspects without limitation,unless a specific security 36 or configuration system 35 or approach isspecifically required by the description of any specific aspect.

FIG. 38 shows an exemplary overview of a computer system 40 as may beused in any of the various locations throughout the system. It isexemplary of any computer that may execute code to process data. Variousmodifications and changes may be made to computer system 40 withoutdeparting from the broader scope of the system and method disclosedherein. Central processor unit (CPU) 41 is connected to bus 42, to whichbus is also connected memory 43, nonvolatile memory 44, display 47,input/output (I/O) unit 48, and network interface card (NIC) 53. I/Ounit 48 may, typically, be connected to peripherals such as a keyboard49, pointing device 50, hard disk 52, real-time clock 51, a camera 57,and other peripheral devices. NIC 53 connects to network 54, which maybe the Internet or a local network, which local network may or may nothave connections to the Internet. The system may be connected to othercomputing devices through the network via a router 55, wireless localarea network 56, or any other network connection. Also shown as part ofsystem 40 is power supply unit 45 connected, in this example, to a mainalternating current (AC) supply 46. Not shown are batteries that couldbe present, and many other devices and modifications that are well knownbut are not applicable to the specific novel functions of the currentsystem and method disclosed herein. It should be appreciated that someor all components illustrated may be combined, such as in variousintegrated applications, for example Qualcomm or Samsungsystem-on-a-chip (SOC) devices, or whenever it may be appropriate tocombine multiple capabilities or functions into a single hardware device(for instance, in mobile devices such as smartphones, video gameconsoles, in-vehicle computer systems such as navigation or multimediasystems in automobiles, or other integrated hardware devices).

In various aspects, functionality for implementing systems or methods ofvarious aspects may be distributed among any number of client and/orserver components. For example, various software modules may beimplemented for performing various functions in connection with thesystem of any particular aspect, and such modules may be variouslyimplemented to run on server and/or client components.

The skilled person will be aware of a range of possible modifications ofthe various aspects described above. Accordingly, the present inventionis defined by the claims and their equivalents.

What is claimed is:
 1. A system for prediction of protein-ligandbioactivity comprising: a computing device comprising a memory and aprocessor; a point-cloud based bioactivity module comprising a firstplurality of programming instructions stored in the memory and operatingon the processor, wherein the first plurality of programminginstructions causes the computing device to: receive a molecularstructure file, wherein the molecular structure file comprises molecularand structural information about at least one protein and one ligand;generate a graph-based neural network of the protein, wherein edges ofthe graph-based neural network of the protein are determined using themolecular structure file; generate a graph-based neural network of theligand, wherein edges of the graph-based neural network of the ligandare determined using the molecular structure file; concatenate a set ofvectors from both the graph-based neural network of the protein and thegraph-based neural network of the ligand; performrestricted-cross-attention learning on the concatenated vectors;generate a single feature vector from the restricted-cross-attentionlearning; use the single feature vector in a feed-forward neural networkto produce one or more outputs selected from the group consisting ofactive or inactive classification, crystalline-structure similarity, andregression analysis; and use the one or more outputs to produce one ormore bioactivity predictions about one or more protein-ligand pairs. 2.The system of claim 1, wherein docking simulations are performed on theprotein and the ligand from the molecular structure file if the proteinand the ligand are coupled.
 3. The system of claim 1, wherein the vectorfrom the graph-based neural network of the protein comprises atomswithin 4 angstroms of the ligand if the protein and the ligand arecoupled.
 4. The system of claim 1, wherein the vector from thegraph-based neural network of the protein comprises atoms of a bindingpocket if the protein and the ligand are decoupled.
 5. The system ofclaim 1, wherein the crystalline-structure similarity prediction is usedto determine the legitimacy of the one or more bioactivity predictions.6. The system of claim 1, wherein the graph-based neural network of theprotein and the graph-based neural network of the ligand are based onone or more transformer convolution classifiers.
 7. The system of claim1, wherein the one or more outputs are used with a loss function toproduce a trained model for bioactivity prediction.
 8. The system ofclaim 1, wherein the machine learning model is a transformer convolutionclassifier.
 9. The system of claim 1, further comprising an output of athree-dimensional visualization of the one or more protein-ligand pairs.10. The system of claim 9, wherein the three-dimensional visualizationcomprises features of molecular interaction properties.
 11. A method forprediction of protein-ligand bioactivity comprising the steps of:receiving a molecular structure file, wherein the molecular structurefile comprises molecular and structural information about at least oneprotein and one ligand; generating a graph-based neural network of theprotein, wherein edges of the graph-based neural network of the proteinare determined using the molecular structure file; generating agraph-based neural network of the ligand, wherein edges of thegraph-based neural network of the ligand are determined using themolecular structure file; concatenating a set of vectors from both thegraph-based neural network of the protein and the graph-based neuralnetwork of the ligand; performing restricted-cross-attention learning onthe concatenated vectors; generating a single feature vector from therestricted-cross-attention learning; using the single feature vector ina feed-forward neural network to produce one or more outputs selectedfrom the group consisting of active or inactive classification,crystalline-structure similarity, and regression analysis; and using theone or more outputs to produce one or more bioactivity predictions aboutone or more protein-ligand pairs.
 12. The method of claim 11, whereindocking simulations are performed on the protein and the ligand from themolecular structure file if the protein and the ligand are coupled. 13.The method of claim 11, wherein the vector from the graph-based neuralnetwork of the protein comprises atoms within 4 angstroms of the ligandif the protein and the ligand are coupled.
 14. The method of claim 11,wherein the vector from the graph-based neural network of the proteincomprises atoms of a binding pocket if the protein and the ligand aredecoupled.
 15. The method of claim 11, wherein the crystalline-structuresimilarity prediction is used to determine the legitimacy of the one ormore bioactivity predictions.
 16. The method of claim 11, wherein thegraph-based neural network of the protein and the graph-based neuralnetwork of the ligand are based on one or more transformer convolutionclassifiers.
 17. The method of claim 11, wherein the one or more outputsare used with a loss function to produce a trained model for bioactivityprediction.
 18. The method of claim 11, wherein the machine learningmodel is a transformer convolution classifier.
 19. The method of claim11, further comprising an output of a three-dimensional visualization ofthe one or more protein-ligand pairs.
 20. The method of claim 19,wherein the three-dimensional visualization comprises features ofmolecular interaction properties.